var title_f23_29_24016="Hypereosinophilic syndromes";
var content_f23_29_24016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 624px\">",
"   <div class=\"ttl\">",
"    Hypereosinophilic syndromes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 604px; height: 478px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Revised classification of HESs. Changes from the previous classification are indicated in red. Dashed arrows identify HES forms for which at least some patients have T cell-driven disease. Classification of myeloproliferative forms has been simplified, and patients with HES and eosinophil hematopoietin-producing T cells in the absence of a T-cell clone are included in the lymphocytic forms of HES.",
"    <div class=\"footnotes\">",
"     IBD: inflammatory bowel disease; CSS: Churg-Strauss syndrome.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Simon H, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:45. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24016=[""].join("\n");
var outline_f23_29_24016=null;
var title_f23_29_24017="Thermal relaxation time in skin";
var content_f23_29_24017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78746&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thermal relaxation time",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thermal relaxation time is the amount of time that it takes an object to return to the ambient temperature following heating. When continuous wave lasers heat targets for longer than the thermal relaxation time, heat diffuses to adjacent tissues, where it can induce collateral damage. When light is emitted in pulses that are shorter than the target's thermal relaxation time, diffusion of heat to adjacent tissues is limited.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24017=[""].join("\n");
var outline_f23_29_24017=null;
var title_f23_29_24018="Intravenous leiomyomatosis MRI";
var content_f23_29_24018=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intravenous leiomyomatosis: magnetic resonance image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vascular invasive leiomyoma. Sagittal T2-weighted image demonstrates large low signal intensity mass (arrow) growing into inferior vena cava (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Leyendecker, JR, Brown, JJ. Practical Guide to Abdominal and Pelvic MRI. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24018=[""].join("\n");
var outline_f23_29_24018=null;
var title_f23_29_24019="Methylfolate: Patient drug information";
var content_f23_29_24019=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methylfolate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32850?source=see_link\">",
"     see \"Methylfolate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6058906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Deplin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low folate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methylfolate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12079 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FF084CEA57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24019=[""].join("\n");
var outline_f23_29_24019=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6058906\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019962\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019964\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019963\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019968\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019970\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019966\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019967\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019971\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019972\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32850?source=related_link\">",
"      Methylfolate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_29_24020="Lichen sclerosus on the wrist";
var content_f23_29_24020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Extragenital lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small papules are present on the wrist of this patient with extragenital lichen sclerosus. Lesions may closely resemble lichen planus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24020=[""].join("\n");
var outline_f23_29_24020=null;
var title_f23_29_24021="Oxaprozin: Patient drug information";
var content_f23_29_24021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oxaprozin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30632?source=see_link\">",
"     see \"Oxaprozin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/56/36743?source=see_link\">",
"     see \"Oxaprozin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Daypro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxaprozin&reg;;",
"     </li>",
"     <li>",
"      Daypro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702648",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oxaprozin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10933 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24021=[""].join("\n");
var outline_f23_29_24021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204388\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204389\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029990\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029992\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029991\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029996\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029997\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029999\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029994\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029995\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030000\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030001\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30632?source=related_link\">",
"      Oxaprozin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/56/36743?source=related_link\">",
"      Oxaprozin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_29_24022="Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)";
var content_f23_29_24022=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tests of the liver's biosynthetic capacity (eg, albumin, coagulation factors, prothrombin time)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24022/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24022/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24022/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24022/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24022/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24022/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/29/24022/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of blood tests are available that reflect the condition of the liver. The most common tests used in clinical practice include the serum aminotransferases, bilirubin, alkaline phosphatase, albumin, and prothrombin time. These tests are often referred to as \"liver function tests\", although this term is somewhat misleading since most do not accurately reflect how well the liver is functioning, and abnormal values can be caused by diseases unrelated to the liver. In addition, these tests may be normal in patients who have advanced liver disease.",
"   </p>",
"   <p>",
"    Several specialized tests have also been developed (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"     indocyanine green",
"    </a>",
"    clearance), which, although uncommonly used in clinical practice, can measure specific aspects of hepatic function.",
"   </p>",
"   <p>",
"    Despite their limitations, liver biochemical and function tests have many applications in clinical medicine:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They provide a noninvasive method to screen for the presence of liver disease. The serum aminotransferases, for example, are part of panel of tests used to screen all blood donors in the United States for the presence of transmissible viruses.",
"     </li>",
"     <li>",
"      They can be used to measure the efficacy of treatments for liver disease (such as immunosuppressant agents for autoimmune hepatitis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link\">",
"       \"Treatment of autoimmune hepatitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They can be used to monitor the progression of a disease such as viral or alcoholic hepatitis.",
"     </li>",
"     <li>",
"      They can reflect the severity of liver disease, particularly in patients who have cirrhosis. As an example, the Child-Pugh score, which incorporates the prothrombin time and serum bilirubin and albumin concentrations, can predict survival (",
"      <a class=\"graphic graphic_table graphicRef78401 \" href=\"UTD.htm?8/21/8540\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pattern of abnormalities on these tests is more accurate than any of the individual tests. Elevation of serum aminotransferases indicates hepatocellular injury, while elevation of the alkaline phosphatase indicates cholestasis. Recognition of patterns that are consistent with specific diseases can prompt appropriate additional testing.",
"   </p>",
"   <p>",
"    The liver biochemical and function tests that are used commonly in clinical practice and that are used occasionally for specific circumstances can be categorized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tests that detect injury to hepatocytes &ndash; Most of these tests measure the activity of hepatic enzymes, such as the aminotransferases, in the circulation. These enzymes are normally intracellular, but are released when hepatocytes are injured. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=see_link\">",
"       \"Liver biochemical tests that detect injury to hepatocytes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tests of the liver's capacity to transport organic anions and metabolize drugs &ndash; These tests measure the liver's ability to clear endogenous or exogenous substances from the circulation. The best studied include serum measurements of bilirubin, bile acids, caffeine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      metabolites, a variety of breath tests, and clearance tests such as bromsulphalein (BSP) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32450?source=see_link\">",
"       indocyanine green",
"      </a>",
"      (ICG).",
"     </li>",
"     <li>",
"      Tests of the liver's biosynthetic capacity &ndash; The most commonly performed tests to assess the biosynthetic capacity of the liver are the serum albumin and the prothrombin time (which requires the presence of clotting factors produced in the liver). Other tests which have been use are the serum concentrations of lipoproteins, ceruloplasmin, ferritin, and alpha 1-antitrypsin.",
"     </li>",
"     <li>",
"      Tests that detect altered immunoregulation or viral hepatitis &ndash; These tests include the immunoglobulins, hepatitis serologies, and specific autoantibodies. Most of these substances are proteins made by B lymphocytes, not by hepatocytes. However, some are quite specific for certain liver diseases, such as antimitochondrial antibodies in primary biliary cirrhosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the role of the serum albumin and prothrombin time in the evaluation of the liver's biosynthetic capacity. The other categories of liver function tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=see_link\">",
"     \"Liver biochemical tests that detect injury to hepatocytes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=see_link\">",
"     \"Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=see_link\">",
"     \"Clinical aspects of serum bilirubin determination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/22/22889?source=see_link\">",
"     \"Tests of the liver's capacity to transport organic anions and metabolize drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SERUM PROTEINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the major site where serum proteins are synthesized. These include albumin and the coagulation factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Albumin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Albumin is quantitatively the most important plasma protein. Approximately 300 to 500 g of albumin is distributed in the body fluids, and the average adult liver synthesizes approximately 15 g per day (200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). The synthesis rate can double in situations in which there is rapid albumin loss or a fall in the serum albumin concentration.",
"   </p>",
"   <p>",
"    The serum albumin concentration reflects the rate of synthesis, rate of degradation, and volume of distribution. Albumin synthesis is regulated by a variety of factors, including nutritional status, serum oncotic pressure, cytokines, and hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. How these factors operate on a cellular level is not precisely known but may involve the formation of albumin messenger ribonucleic acid (mRNA) polysomes within the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Substances that stimulate albumin synthesis increase the efficiency of this process. By contrast, inhibitory substances associated with inflammatory states, such as tumor necrosis factor and interleukin-1, impede albumin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known about the site of degradation of albumin. The half-life of albumin in serum is approximately 20 days, with 4 percent of the total albumin pool being degraded daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoalbuminemia does not always reflect the presence of hepatic synthetic dysfunction since a variety of other conditions may be responsible including systemic inflammation, the nephrotic syndrome, and malnutrition. Some general observations can be made in patients with liver disease who do not appear to have these other disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum albumin concentrations tend to be normal in acute viral hepatitis, drug-related hepatotoxicity, and obstructive jaundice. The possibility of chronic liver disease should be considered when the serum albumin concentration is below 3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"      in these patients.",
"     </li>",
"     <li>",
"      Hypoalbuminemia is more common in chronic liver disorders such as cirrhosis. The fall in albumin concentration usually reflects severe liver damage with reduced albumin synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/7\">",
"       7",
"      </a>",
"      ]. An exception may occur in patients with ascites who may become hypoalbuminemic despite good hepatic synthetic function because of the often marked increase in plasma volume [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The serum albumin concentration should",
"    <strong>",
"     not",
"    </strong>",
"    be measured for screening in patients in whom there is no suspicion of liver disease. This was illustrated in a study that included 449 patients seen in a general medical practice in whom serum albumin was measured routinely; 13 percent had an abnormal value, which was found to be clinically significant in only two patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum albumin levels persistently above the laboratory's reference range are usually observed in normal people who are at the extreme right of the bell-shaped curve. Acute hyperalbuminemia is seen most commonly in patients with volume depletion, in whom it is often associated with hemoconcentration as well. A case report described hyperalbuminemia in a patient consuming a high-protein diet [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/10\">",
"     10",
"    </a>",
"    ]. Hyperalbuminemia is also theoretically possible in patients with genetic variants that prolong the half-life of albumin in serum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Coagulation factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver is the major site of synthesis of 11 blood coagulation proteins. These include",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Factor I (fibrinogen)",
"     </li>",
"     <li>",
"      Factor II (prothrombin)",
"     </li>",
"     <li>",
"      Factor V",
"     </li>",
"     <li>",
"      Factor VII",
"     </li>",
"     <li>",
"      Factor IX",
"     </li>",
"     <li>",
"      Factor X",
"     </li>",
"     <li>",
"      Factor XII",
"     </li>",
"     <li>",
"      Factor XIII",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clotting factor deficiency frequently occurs during the course of liver disease. These proteins can be measured individually or indirectly by more general measures of clotting ability such as the prothrombin time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged prothrombin time is not specific for liver disease, since it can result from various congenital or acquired conditions including consumption of clotting factors (such as disseminated intravascular coagulation or severe gastrointestinal bleeding) and certain drugs. When these conditions have been excluded, a prolonged prothrombin time usually reflects one of two disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A deficiency of vitamin K, which may be induced by inadequate dietary intake, prolonged obstructive jaundice, intestinal malabsorption, or the administration of antibiotics that alter the gut flora. In such cases, the prothrombin time typically returns to normal within 24 hours after a single parenteral injection of vitamin K. This response is particularly helpful diagnostically when evaluating patients who are jaundiced.",
"     </li>",
"     <li>",
"      Poor utilization of vitamin K due to advanced parenchymal liver disease. Vitamin K supplementation is generally ineffective in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prothrombin time does not accurately reflect the coagulation status of patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/11\">",
"     11",
"    </a>",
"    ] or correlate with the risk of bleeding because of concomitant reductions in the hepatic synthesis of anti-hemostatic factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link\">",
"     \"Coagulation abnormalities in patients with liver disease\"",
"    </a>",
"    .) On the other hand, the magnitude of elevation of the prothrombin time above control correlates with prognosis in some conditions. As an example, an elevation more than five seconds above control should raise concern about a fulminant course in patients who have acute viral, toxic, or alcoholic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A prothrombin time above 100 sec is considered an indication for liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .) However, some patients recover despite marked elevations in the prothrombin time, particularly those who have",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose. A progressive decline in the prothrombin time in such patients usually heralds recovery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     International normalized ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The international normalized ratio (INR) is often used to express the degree of anticoagulation in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . The INR standardizes prothrombin time measurement based upon characteristics of the thromboplastin reagent used in the laboratory. This helps to eliminate variability between measurements in which different thromboplastin reagents are used, and assure a stable level of anticoagulation.",
"   </p>",
"   <p>",
"    In contrast to its use in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the INR may not be the best expression of coagulation derangement in patients with liver failure, especially if the same thromboplastin reagents are not consistently used for measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. This was illustrated in a study in which various expressions of the prothrombin time (seconds above control, ratio to control, activity percentage, and INR) were evaluated in 27 patients with chronic or acute liver failure compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/14\">",
"     14",
"    </a>",
"    ]. Only the activity percentage expression eliminated variability in the prothrombin time results in individual patients when using different thromboplastin reagents. This observation implies that, in an individual patient with liver failure, interpretation of changes in the INR may only be accurate when the same thromboplastin is used. Furthermore, comparison of the degree of synthetic dysfunction using the INR in patients who underwent testing at centers using different thromboplastin reagents may not be valid [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This may be particularly relevant when prioritizing patients for liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A new standardization method for the INR is needed to make the INR more applicable in patients with liver disease. At least two such modifications have been proposed, both of which reduced variability when used for calculation of the MELD score [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link\">",
"     \"Coagulation abnormalities in patients with liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Des-gamma-carboxy prothrombin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The synthesis of factors II, VII, IX, and X requires vitamin K for the addition of carboxylic acid moieties to the gamma position of glutamic acid residues in these proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\"",
"    </a>",
"    .) Gamma carboxylation permits these proteins to bind calcium, which is necessary for them to function normally. An abnormal prothrombin form (des-gamma-carboxy prothrombin) is released in the absence of vitamin K, in the presence of vitamin K antagonists such as warfarin, and by certain tumors, such as hepatocellular carcinoma (HCC). Des-gamma-carboxy prothrombin is produced by the malignant hepatocyte which appears to acquire a posttranslational defect in the vitamin K-dependent carboxylase system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24022/abstract/21\">",
"     21",
"    </a>",
"    ]. The serum concentration of des-gamma-carboxy prothrombin has been evaluated for screening patients at risk for hepatocellular carcinoma but appears to have lower sensitivity than alpha fetoprotein (AFP) for tumors &lt;3 cm. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link\">",
"     \"Clinical features and diagnosis of primary hepatocellular carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H188821106\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most commonly performed tests to assess the biosynthetic capacity of the liver are the serum albumin and the prothrombin time (which is based upon the presence of clotting factors produced in the liver). Other tests which have been used are the serum concentrations of lipoproteins, ceruloplasmin, ferritin, and alpha 1-antitrypsin.",
"     </li>",
"     <li>",
"      The liver is the major site where serum proteins are synthesized. These include albumin and the coagulation factors. The clinical significance of low and high values is described above. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Serum proteins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to its use in patients on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , the international normalized ratio (INR) may not be the best expression of coagulation derangement in patients with liver failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=see_link\">",
"       \"Coagulation abnormalities in patients with liver disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H7\">",
"       'International normalized ratio'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25929705\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/1\">",
"      Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology 1988; 8:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/2\">",
"      Pietrangelo A, Panduro A, Chowdhury JR, Shafritz DA. Albumin gene expression is down-regulated by albumin or macromolecule infusion in the rat. J Clin Invest 1992; 89:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/3\">",
"      Sun X, Martin V, Weiss RH, Kaysen GA. Selective transcriptional augmentation of hepatic gene expression in the rat with Heymann nephritis. Am J Physiol 1993; 264:F441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/4\">",
"      Moshage HJ, Janssen JA, Franssen JH, et al. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest 1987; 79:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/5\">",
"      Perlmutter DH, Dinarello CA, Punsal PI, Colten HR. Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 1986; 78:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/6\">",
"      Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 1984; 311:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/7\">",
"      Rothschild MA, Oratz M, Zimmon D, et al. Albumin synthesis in cirrhotic subjects with ascites studied with carbonate-14C. J Clin Invest 1969; 48:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/8\">",
"      Lieberman FL, Reynolds TB. Plasma volume in cirrhosis of the liver: its relation of portal hypertension, ascites, and renal failure. J Clin Invest 1967; 46:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/9\">",
"      Veldhuyzen van Zanten SJ, Depla AC, Dekker PC, et al. The clinical importance of routine measurement of liver enzymes, total protein and albumin in a general medicine outpatient clinic: a prospective study. Neth J Med 1992; 40:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/10\">",
"      Mutlu EA, Keshavarzian A, Mutlu GM. Hyperalbuminemia and elevated transaminases associated with high-protein diet. Scand J Gastroenterol 2006; 41:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/11\">",
"      Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/12\">",
"      O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/13\">",
"      Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology 1995; 21:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/14\">",
"      Robert A, Chazouill&egrave;res O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996; 24:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/15\">",
"      Denson KW, Reed SV, Haddon ME, et al. Comparative studies of rabbit and human recombinant tissue factor reagents. Thromb Res 1999; 94:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/16\">",
"      Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet 2002; 359:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/17\">",
"      Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/18\">",
"      Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/19\">",
"      Bellest L, Eschw&egrave;ge V, Poupon R, et al. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007; 46:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/20\">",
"      Nelsestuen GL, Zytkovicz TH, Howard JB. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 1974; 249:6347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24022/abstract/21\">",
"      Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18:990.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3566 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24022=[""].join("\n");
var outline_f23_29_24022=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H188821106\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SERUM PROTEINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Albumin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      International normalized ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Des-gamma-carboxy prothrombin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H188821106\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25929705\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3566\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3566|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/21/8540\" title=\"table 1\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32937?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=related_link\">",
"      Clinical aspects of serum bilirubin determination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/7/33914?source=related_link\">",
"      Coagulation abnormalities in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19353?source=related_link\">",
"      Enzymatic measures of cholestasis (eg, alkaline phosphatase, 5&rsquo;-nucleotidase, gamma-glutamyl transpeptidase)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/63/21494?source=related_link\">",
"      Liver biochemical tests that detect injury to hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/22/22889?source=related_link\">",
"      Tests of the liver's capacity to transport organic anions and metabolize drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=related_link\">",
"      Vitamin K and the synthesis of gamma carboxyglutamic acid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_29_24023="Pregnancy in homeless women";
var content_f23_29_24023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy in homeless women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24023/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24023/contributors\">",
"     Nicole Ruddock Hall, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24023/contributors\">",
"     Sheryl D Perriatt, BSN, RNC, FAACM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24023/contributors\">",
"     Casey W Hedges, LMSW",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24023/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24023/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24023/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24023/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/29/24023/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1158228770\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homelessness disproportionately affects women and children: women represent approximately 80 percent of adults in homeless families in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/1\">",
"     1",
"    </a>",
"    ].&nbsp;Homeless women are at higher risk of having chronic illnesses, infectious diseases, substance abuse problems, mental illness, and being a victim of sexual or domestic violence than women who are not homeless [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. They are also less likely to have insurance, social support, income, or access to preventive health services [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attention to the following principles is likely to improve results when providing care for homeless people [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outreach to engage those in need of health care services",
"     </li>",
"     <li>",
"      Respect for each patient, regardless of circumstances",
"     </li>",
"     <li>",
"      Cultivation of trust and rapport between the health care provider and patient",
"     </li>",
"     <li>",
"      Flexibility in providing health care services, including location, hours of service, missed appointments, and treatment approaches",
"     </li>",
"     <li>",
"      Attention to the basic survival needs of homeless people. Health care may not be the patient&rsquo;s priority until those needs are met. &nbsp;",
"     </li>",
"     <li>",
"      Multidisciplinary case management to coordinate services (medical and nonmedical)",
"     </li>",
"     <li>",
"      Clinical expertise to address complex clinical problems",
"     </li>",
"     <li>",
"      Continuing care until the patient&rsquo;s life situation is stabilized",
"     </li>",
"     <li>",
"      Help with housing options, including programs combining housing with services (eg, childcare, substance abuse, mental health)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss issues specific to the evaluation and care of homeless pregnant women. Homelessness in other populations is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44185?source=see_link\">",
"     \"Health care of homeless persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1158229001\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant homeless women are typically younger than nonpregnant homeless women, and frequently have a history of family disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/6\">",
"     6",
"    </a>",
"    ]. The homeless teenager is often the product of domestic instability",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    poverty [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/7\">",
"     7",
"    </a>",
"    ]. In a study that reviewed trends of homeless women in the US from 2000 to 2007, homelessness was associated with Black and Hispanic races, being unmarried, uninsured, receiving government aid, and not taking a multivitamin supplement before pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/8\">",
"     8",
"    </a>",
"    ]. The prevalence of homelessness among women in this study was 4 percent, which is about 1 in every 26 women of reproductive age in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1158229055\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF HOMELESSNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homelessness has many causes and homeless pregnant women are a heterogeneous group. Domestic and sexual violence is the leading cause of homelessness in women, as 20 to 50 percent of all homeless women and children become homeless as a direct result of trying to escape domestic violence [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/4\">",
"     4",
"    </a>",
"    ]. Women continue to be at risk of violence in homeless shelters or when living on the streets [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/9\">",
"     9",
"    </a>",
"    ]. Some shelters do not accept pregnant women out of concern of liability if the woman experiences complications or problems while in the shelter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44185?source=see_link&amp;anchor=H4#H4\">",
"     \"Health care of homeless persons\", section on 'Causes of homelessness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors include joblessness, inadequate social or financial support, substance abuse, mental illness, previous incarceration, loss of a home (eg, fire, eviction, building condemned or sold), and discrimination in housing because of ethnicity, number of children, receipt of welfare, or pregnancy. Pregnancy or pregnancy complications may lead to loss of employment and, in turn, loss of income to pay for housing.",
"   </p>",
"   <p>",
"    For a teenager, pregnancy may be the precipitating event that leads to her voluntarily or involuntarily leaving her parents&rsquo; home. Psychosocial issues are also common in this population. A three-year study of pregnancy and motherhood in unaccompanied homeless women aged 16 to 19 years observed high rates of mental illness and substance abuse: approximately 32 percent suffered from major depressive disorder, 65 percent from a conduct disorder, and 51 percent from posttraumatic stress disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/11\">",
"     11",
"    </a>",
"    ]. The rates of alcohol and drug abuse were 21 and 35 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9105603\">",
"    <span class=\"h1\">",
"     PREVALENCE OF PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most reports suggest pregnancy is more prevalent in homeless women, but accurate data are difficult to obtain. In one study of 764 homeless women in Los Angeles, 28 percent reported being pregnant in the past year and almost 75 percent of these pregnancies were unintended [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/12\">",
"     12",
"    </a>",
"    ]. By comparison, about 10 percent of all reproductive aged women in the United States become pregnant each year and approximately 50 percent of these pregnancies are unintended [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Unintended pregnancies are more common in homeless women because of the many barriers to contraceptive use in this population, including lack of education about, and access to, free or low cost contraceptives, lack of storage space for contraceptives, an irregular and unpredictable lifestyle, involvement in the sex trade, victimization by sexual violence, and partners unwilling to use condoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]. In addition, homeless teenagers may avoid contraception because they perceive pregnancy as an opportunity to form stable bonds and restructure their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These issues were illustrated in a study of 15 homeless pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/10\">",
"     10",
"    </a>",
"    ]. Although pregnancy was sometimes the precipitating factor that caused these women to become homeless, the majority of women became pregnant while they were homeless. From their self-reports, factors that contributed to becoming pregnant included victimization, economic survival, lack of access to contraceptives, the need for closeness and intimacy, uncertain fertility, and hope for the future. For some women, their pregnancy was their only source of joy and a catalyst for them to resolve past problems and seek a better life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1158229143\">",
"    <span class=\"h1\">",
"     PREGNANCY OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have examined pregnancy outcomes in the homeless. The risk of adverse maternal and fetal outcomes is increased in homeless pregnant women due to poor access to health care, poor nutrition, lack of housing, substance abuse, exposure to violence, a high prevalence of infection, and medical co-morbidities; the most common complications are preterm delivery and low birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/10,16-19\">",
"     10,16-19",
"    </a>",
"    ].&nbsp;As an example, a Canadian study found that pregnant women who were homeless or had inadequate housing had a three-fold increase in risk of preterm delivery or small for gestational age infant and a seven-fold increase in risk of birth weight &lt;2000 grams compared to women who were not homeless, after adjustment for risk factors such as maternal age, number of previous pregnancies, and smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/17\">",
"     17",
"    </a>",
"    ]. Homeless substance abusers were at even higher risk of these outcomes. In another study, none of the homeless women had consistent prenatal care and they were not educated about, and could not differentiate between, normal and pathological signs and symptoms related to pregnancy.",
"   </p>",
"   <p>",
"    A population-based assessment of homeless families in New York City from 2001 to 2003 showed that morbidity and mortality are higher among homeless children, even when compared to children in low-income families [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9105611\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, homeless shelters should screen women of reproductive age for pregnancy in order to allow early identification and referral to appropriate sources of prenatal care. Some homeless women do not even know that they are pregnant because their menstrual periods have stopped or become irregular [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/10\">",
"     10",
"    </a>",
"    ]. Most seek health care from an urgent care or emergency medicine setting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1170194956\">",
"    <span class=\"h2\">",
"     Barriers to receiving health care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major barriers to prenatal care are site-related factors such as distance to the prenatal care site, lack of transportation, and long wait times for appointments [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/6\">",
"     6",
"    </a>",
"    ]. Socioeconomic factors such as financial constraints and lack of insurance coverage contribute to poor compliance with visits and recommendations for drug therapy. Health care demands compete with needs for food, clothing, and shelter. Other significant limitations are lack of knowledge about where or how to acquire prenatal care and fear of how the homeless woman will be perceived or treated by health care providers. For example, women with substance abuse issues, mental illness, or undocumented resident status may fear being reported to the authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/22\">",
"     22",
"    </a>",
"    ] and women with children may fear that their children will be taken away [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, all states provide medical insurance (Medicaid) to low income pregnant women who have no medical insurance or inadequate insurance. The income threshold varies among states, but the minimum is a family income at or below 133 percent of the Federal poverty level. Women who earn too much money to qualify for Medicaid when they were not pregnant may qualify when they become pregnant and when they have a child because the income threshold is different for these groups. Pregnant women are usually given priority in determining Medicaid eligibility, and will receive qualification within two to four weeks of submitting an application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1158229101\">",
"    <span class=\"h2\">",
"     Prenatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal providers should identify patients who may be homeless or at risk of becoming homeless; pregnant women may be reluctant to voluntarily reveal their homelessness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. Prenatal care of homeless women should include referral for available resources, social support, and screening for conditions more prevalent in the homeless population. Prenatal care should be provided without bias or prejudice and with empathy and effort to establish rapport so that a trusting relationship can be developed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/4\">",
"     4",
"    </a>",
"    ]. The provider should be honest and let the patient know when tests for drugs and reportable diseases are being performed and when the provider is obligated to notify child protection services. Treatment regimens should be simplified whenever possible and more cost effective options offered, when available. Treatment should not be withheld due to assumptions about lack of adherence. It is helpful to be flexible in scheduling appointments.",
"   </p>",
"   <p>",
"    A standard initial prenatal assessment should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial prenatal assessment and patient education\", section on 'Laboratory tests'",
"    </a>",
"    .). However, for a homeless woman, the initial prenatal care visit may be the only opportunity to provide care prior to delivery; therefore, it is important to assess what information is critical and prioritize accordingly. Information should be relevant to the patient&rsquo;s circumstances and living situation, and provided in small increments.",
"   </p>",
"   <p>",
"    Screening for the following problems is particularly important in homeless women since these problems are more prevalent in this population.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Domestic violence (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link\">",
"       \"Intimate partner violence: Diagnosis and screening\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Substance abuse (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link&amp;anchor=H3#H3\">",
"       \"Overview of illicit drug use in pregnant women\", section on 'Screening for drug use'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sexual abuse (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=see_link\">",
"       \"Intimate partner violence: Diagnosis and screening\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mental illness (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=see_link&amp;anchor=H25#H25\">",
"       \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\", section on 'Screening'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete physical examination is performed, with attention to establishing gestational age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial prenatal assessment and patient education\", section on 'History and physical examination'",
"    </a>",
"    .) The skin should be examined carefully, as skin conditions are among the most common diagnoses in clinics for the homeless. Lice, scabies and secondary bacterial complications are highly contagious problems endemic to homeless people. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44185?source=see_link&amp;anchor=H18#H18\">",
"     \"Health care of homeless persons\", section on 'Skin and foot problems'",
"    </a>",
"    .). Dental health and visual acuity should be assessed, as these needs may have been neglected.",
"   </p>",
"   <p>",
"    Routine prenatal laboratory tests are obtained, as well as additional testing based on patient-specific risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial prenatal assessment and patient education\", section on 'Laboratory tests'",
"    </a>",
"    .). For example, the rate of HIV infection among homeless youth is substantially higher than the national rate for youth; 2.3 percent versus 0.1 percent nationally [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition to routine screening for chlamydia, syphilis, hepatitis B, and HIV, we suggest screening homeless women for:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gonorrhea (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=see_link&amp;anchor=H11473906#H11473906\">",
"       \"Diagnosis of gonococcal infections\", section on 'General background'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatitis C (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"       \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tuberculosis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44185?source=see_link&amp;anchor=H17#H17\">",
"       \"Health care of homeless persons\", section on 'Tuberculosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=see_link\">",
"       \"Tuberculosis in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Illicit drugs (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link&amp;anchor=H17#H17\">",
"       \"Substance use disorders: Principles for recognition and assessment in general medical care\", section on 'Drug testing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunizations are likely to have been neglected. Immunization records should be obtained, if available, and missed immunizations should be provided. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link\">",
"     \"Immunizations during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Health care providers should be aware of local resources for the homeless and how to access them. Case management or social workers should be involved in patient care so they can provide information on shelters for women and children or affordable housing, transportation to and from appointments and the hospital, mental health and substance abuse treatment programs, food banks, clothing, child care resources, legal aid, and crisis lines. For women who do not live in shelters that provide meals, obtaining, transporting, storing, and cooking nutritious food can be a major problem. Substance abusers are prone to undernutrition and malnutrition, and women with diabetes may not have access to antihyperglycemic drugs or be able to adhere to a regular schedule of meals. Preexisting mental health issues may be exacerbated by stress and pregnancy-related mood changes. Social workers are often familiar with staff at local shelters, government agencies for housing vouchers, and other resources, which facilitates obtaining these resources for patients who need them.",
"   </p>",
"   <p>",
"    Homeless women also need to be prepared for labor and delivery, postpartum issues, care of the newborn, and parenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9105659\">",
"    <span class=\"h2\">",
"     Labor and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some homeless women may attempt to speed the onset of labor with castor oil or cocaine because of the discomforts of late pregnancy, which are particularly problematic for women living in the streets or in a shelter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/10\">",
"     10",
"    </a>",
"    ]. For homeless women who first present in labor during the third trimester, we suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment of gestational age and",
"      <span class=\"nowrap\">",
"       medical/obstetrical",
"      </span>",
"      disorders",
"     </li>",
"     <li>",
"      Routine laboratory tests (complete blood count, blood type and antibody screen, rubella immunity, urine culture, cervical cytology), as well as screening for sexually transmitted infections, tuberculosis, illicit drugs, and diabetes (random blood glucose concentration)",
"     </li>",
"     <li>",
"      Rapid HIV testing (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link&amp;anchor=H17#H17\">",
"       \"Diagnostic assays for HIV infection\", section on 'Rapid antibody tests'",
"      </a>",
"      ), as intrapartum antiretroviral therapy in HIV infected women can decrease perinatal transmission (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"       \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Group B streptococcus (GBS) antibiotic prophylaxis if the culture status is unknown (culture not performed or result not available)",
"      <strong>",
"       and",
"      </strong>",
"      intrapartum fever (&ge;100.4&ordm;F, &ge;38&ordm;C)",
"      <strong>",
"       or",
"      </strong>",
"      preterm labor (&lt;37 weeks of gestation)",
"      <strong>",
"       or",
"      </strong>",
"      prolonged rupture of membranes (&ge;18 hours). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"       \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9105667\">",
"    <span class=\"h2\">",
"     Postpartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;All women should be encouraged to breastfeed, unless there are contraindications (eg, HIV infection, active tuberculosis or herpetic breast lesions). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=see_link\">",
"     \"Breastfeeding: Parental education and support\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=see_link\">",
"     \"Maternal and economic benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3090189\">",
"    <span class=\"h3\">",
"     Discharge planning",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is the responsibility of the hospital staff to ensure the mother is prepared to care for her baby, despite the many obstacles that homelessness may create [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Discharge planning involves the various members of the interdisciplinary team. It is important to view every patient individually; each situation should be handled on a case-by-case basis, so there is no definitive protocol as to what must occur postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial assessment should address living situation, support system, knowledge of childcare issues, resources, and issues regarding substance abuse and mental health. Many homeless women will be reluctant to honestly share this information and worry about being judged by the hospital staff; however, many are eager and receptive to getting help. Their dignity should be respected, and their strengths and accomplishments recognized.",
"   </p>",
"   <p>",
"    The decision to involve Children&rsquo;s Protective Services (CPS) is made after evaluating whether or not the mother is making healthy choices for her child. Is she living on the streets or does she have housing? Living in a shelter may show that she has made some choices to regain the stability that her child will need. Many shelters provide counseling, day care, and assistance with other basic needs. This shelter may be the closest thing to a home that this mother and her child will have. If this is the case, and there are no other high-risk concerns, the usual course of action would be to assist her with resources and provide encouragement. However, if a mother plans on returning to life on the streets with her newborn, or if there are additional concerns regarding the safety and well-being of the baby, a report to CPS is generally needed. When indicated, involving CPS will not only help to ensure the safety of the baby, but can also help the mother to get the help she may need.",
"   </p>",
"   <p>",
"    After identifying the woman&rsquo;s needs, the case manager and social worker often collaborate to ensure these needs are met prior to her discharge. It is the role of the case manager to assist with home health needs, medication assistance, identification of a primary care physician for the child, and help in scheduling follow-up appointments. The social worker&rsquo;s role involves resource assistance, connection to community services, and advocating for the patient.",
"   </p>",
"   <p>",
"    When CPS is not involved, there are other community case management programs available to address these needs and to support the mother in her time of transition. These referrals are made by the social worker prior to the mother&rsquo;s discharge. At the time of discharge, assisting with transportation is generally required. Some shelters offer transportation to their residents; when this is not an option, the social worker will assist with transportation back to the shelter by providing a taxi voucher or utilizing transportation services through the mother&rsquo;s insurance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. An infant car seat is generally mandated by state law, even for a short ride from the hospital to the shelter. If the mother cannot purchase or borrow a car seat, then the social worker can help arrange for one.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3090297\">",
"    <span class=\"h3\">",
"     Legal responsibilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to define a physician&rsquo;s legal responsibilities related to the disposition of a homeless patient, as laws vary by state. Each case should be assessed on an individual basis with social work and case management to determine whether the patient and her infant are being discharged to a safe environment. Ideally, the involvement of a multidisciplinary team should ensure a smooth transition from the hospital. However, any concern with the child&rsquo;s welfare or the mother&rsquo;s ability to make choices that do not endanger her newborn should prompt a report to Children&rsquo;s Protective Services. Complicated cases may require involvement of the hospital&rsquo;s legal office or ethics committee, depending on the specific case. General information on discharge planning for the homeless can be obtained from the National Health Care for the Homeless Council at",
"    <a class=\"external\" href=\"file://www.nhchc.org/\">",
"     www.nhchc.org",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24023/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1170194794\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Homelessness disproportionately affects women and children. Domestic and sexual violence is the leading cause of homelessness in women. Pregnancy is more common among homeless women than women who are not homeless. Pregnancy may be the precipitating event that leads a teenager to voluntarily or involuntarily leave her parents&rsquo; home. (See",
"      <a class=\"local\" href=\"#H1158228770\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1158229001\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1158229055\">",
"       'Etiology of homelessness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of adverse maternal and fetal outcomes is increased in homeless pregnant women due to poor access to health care, poor nutrition, lack of housing, substance abuse, exposure to violence, a high prevalence of infection, and medical co-morbidities. The most common complications are preterm delivery and low birth weight. (See",
"      <a class=\"local\" href=\"#H1158229143\">",
"       'Pregnancy outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Financial, physical, and psychosocial barriers impede homeless pregnant women from receiving prenatal care. (See",
"      <a class=\"local\" href=\"#H1170194956\">",
"       'Barriers to receiving health care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Homeless pregnant women should receive routine prenatal care tailored to their specific needs, with emphasis on assessment of basic needs (eg, housing, food, clothing, transportation to appointments; evaluation for domestic violence, sexual abuse, substance abuse, mental illness, sexually transmitted diseases, tuberculosis; and examination of the skin, teeth and gums, and vision). (See",
"      <a class=\"local\" href=\"#H1158229101\">",
"       'Prenatal care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discharge planning involves the various members of the interdisciplinary team to ensure that the basic needs of the mother and baby are met. The decision to involve Children&rsquo;s Protective Services (CPS) is made after evaluating whether or not the mother is making healthy choices for her child. (See",
"      <a class=\"local\" href=\"#H3090189\">",
"       'Discharge planning'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Department of Housing and Urban Development (US). The 2008 annual homeless assessment report to Congress. HUD, Washington DC 2009. Available at: file://www.hudhre.info/documents/4thHomelessAssessmentReport.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/2\">",
"      Cheung AM, Hwang SW. Risk of death among homeless women: a cohort study and review of the literature. CMAJ 2004; 170:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/3\">",
"      Zlotnick C, Zerger S. Survey findings on characteristics and health status of clients treated by the federally funded (US) Health Care for the Homeless Programs. Health Soc Care Community 2009; 17:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/4\">",
"      American College of Obstetricians and Gynecologists. Committee on Health Care for Underserved Women. Committee opinion no. 454: Healthcare for homeless women. Obstet Gynecol 2010; 115:396.",
"     </a>",
"    </li>",
"    <li>",
"     McMurray-Avila, M, Gelberg, L, Breakey, WR. Balancing act: Clinical practices that respond to the needds of homeless people. file://aspe.hhs.gov/homeless/symposium/8-Clinical.htm (Accessed on September 08, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/6\">",
"      Bloom KC, Bednarzyk MS, Devitt DL, et al. Barriers to prenatal care for homeless pregnant women. J Obstet Gynecol Neonatal Nurs 2004; 33:428.",
"     </a>",
"    </li>",
"    <li>",
"     Scappaticci A, Blay S. Homeless teen mothers: social and psychological aspects. J Public Health 2009; 17:19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/8\">",
"      Richards R, Merrill RM, Baksh L. Health behaviors and infant health outcomes in homeless pregnant women in the United States. Pediatrics 2011; 128:438.",
"     </a>",
"    </li>",
"    <li>",
"     Jasinski, JL, Wesely, JK, Mustaine, E, Wright, JD. The experience of violence in the lives of homeless women: a research report. University of Central Florida, Orlando FL 2005. Available at:file://www.ncjrs.gov/pdffiles1/nij/grants/211976.pdf.",
"    </li>",
"    <li>",
"     Killon, CM. Special health care needs of homeless pregnant women. Advances in Nursing Science 1995; 18:44.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/11\">",
"      Crawford DM, Trotter EC, Hartshorn KJ, Whitbeck LB. Pregnancy and mental health of young homeless women. Am J Orthopsychiatry 2011; 81:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/12\">",
"      Gelberg L, Leake BD, Lu MC, et al. Use of contraceptive methods among homeless women for protection against unwanted pregnancies and sexually transmitted diseases: prior use and willingness to use in the future. Contraception 2001; 63:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/13\">",
"      Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 2006; 38:90.",
"     </a>",
"    </li>",
"    <li>",
"     Ventura, SJ, Martin, JA, Curtin, SC, et al. Births: final data for 1999. Natl Vital Stat Rep 2001; 49:1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/15\">",
"      Gelberg L, Lu MC, Leake BD, et al. Homeless women: who is really at risk for unintended pregnancy? Matern Child Health J 2008; 12:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/16\">",
"      Beal AC, Redlener I. Enhancing perinatal outcome in homeless women: the challenge of providing comprehensive health care. Semin Perinatol 1995; 19:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/17\">",
"      Little M, Shah R, Vermeulen MJ, et al. Adverse perinatal outcomes associated with homelessness and substance use in pregnancy. CMAJ 2005; 173:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/18\">",
"      Stein JA, Lu MC, Gelberg L. Severity of homelessness and adverse birth outcomes. Health Psychol 2000; 19:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/19\">",
"      Paterson CM, Roderick P. Obstetric outcome in homeless women. BMJ 1990; 301:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/20\">",
"      Kerker BD, Bainbridge J, Kennedy J, et al. A population-based assessment of the health of homeless families in New York City, 2001-2003. Am J Public Health 2011; 101:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/21\">",
"      Salit SA, Kuhn EM, Hartz AJ, et al. Hospitalization costs associated with homelessness in New York City. N Engl J Med 1998; 338:1734.",
"     </a>",
"    </li>",
"    <li>",
"     Roberts, S, Pies, C. Complex calculations: how drug use during pregnancy becomes a barrier to prenatal care. Matern Child Health J; :. [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24023/abstract/23\">",
"      Allen DM, Lehman JS, Green TA, et al. HIV infection among homeless adults and runaway youth, United States, 1989-1992. Field Services Branch. AIDS 1994; 8:1593.",
"     </a>",
"    </li>",
"    <li>",
"     Texas Health and Human Services Commission, Case Management Optimization. Best Practices and Emerging Trends in Case Management. file://www.hhsc.state.tx.us/about_hhsc/reports/CaseManagement_BestPractices.pdf (Accessed on September 27, 2010).",
"    </li>",
"    <li>",
"     American Nurses Association. Code of ethics for nurses 2001. Available at file://www.nursingworld.org (Accessed on September 27, 2010).",
"    </li>",
"    <li>",
"     Texas State Board of Social Worker Examiners. Title 22 (Examining Boards), Texas Administrative Code, Part 34, Chapter 781. Rules Relating to the Licensing and Regulation of Social Workers. Available at file://www.dshs.state.tx.us/socialwork/sw_rules.pdf (Accessed on September 27, 2010).",
"    </li>",
"    <li>",
"     National Health Care for the Homeless Council at file://www.nhchc.org/discharge.html (Accessed on September 27, 2010).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14183 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24023=[""].join("\n");
var outline_f23_29_24023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1170194794\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1158228770\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1158229001\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1158229055\">",
"      ETIOLOGY OF HOMELESSNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9105603\">",
"      PREVALENCE OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1158229143\">",
"      PREGNANCY OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9105611\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1170194956\">",
"      Barriers to receiving health care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1158229101\">",
"      Prenatal care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9105659\">",
"      Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9105667\">",
"      Postpartum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3090189\">",
"      - Discharge planning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3090297\">",
"      - Legal responsibilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1170194794\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42616?source=related_link\">",
"      Breastfeeding: Parental education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/35/26166?source=related_link\">",
"      Diagnosis of gonococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44185?source=related_link\">",
"      Health care of homeless persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/15/6393?source=related_link\">",
"      Intimate partner violence: Diagnosis and screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=related_link\">",
"      Maternal and economic benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29096?source=related_link\">",
"      Tuberculosis in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_29_24024="Quinapril: Drug information";
var content_f23_29_24024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinapril: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/24/15749?source=see_link\">",
"    see \"Quinapril: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/24/42375?source=see_link\">",
"    see \"Quinapril: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Accupril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accupril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral: Initial: 5 mg once or twice daily, titrated at weekly intervals to 20-40 mg daily in 2 divided doses; target dose (heart failure): 20 mg twice daily (ACC/AHA 2009 Heart Failure Guidelines)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 10-20 mg once daily, adjust according to blood pressure response at peak and trough blood levels; initial dose may be reduced to 5 mg in patients receiving diuretic therapy if the diuretic is continued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Usual dose range (JNC 7):",
"     </i>",
"     10-40 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4476059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/24/42375?source=see_link\">",
"      see \"Quinapril: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Hypertension (unlabeled use):",
"     </b>",
"     Oral: Initial 5-10 mg once daily; maximum: 80 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 2.5-5 mg/day; increase dosage at increments of 2.5-5 mg at 1- to 2-week intervals; adjust for renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F216358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lower initial doses should be used; after initial dose (if tolerated), administer initial dose twice daily; may be increased at weekly intervals to optimal response:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Heart failure: Oral: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30 mL/minute: Administer 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer 2.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hypertension: Oral: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: Administer 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-60 mL/minute: Administer 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute: Administer 2.5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F216359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In patients with alcoholic cirrhosis, hydrolysis of quinapril to quinaprilat is impaired; however, the subsequent elimination of quinaprilat is unaltered.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Accupril&reg;: 5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Accupril&reg;: 10 mg, 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; treatment of heart failure",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F216388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of left ventricular dysfunction after myocardial infarction; pediatric hypertension; to delay the progression of nephropathy and reduce risks of cardiovascular events in hypertensive patients with type 1 or 2 diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accupril&reg; may be confused with Accolate&reg;, Accutane&reg;, AcipHex&reg;, Monopril&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accupril [U.S., Canada] may be confused with Acepril which is a brand name for captopril [Great Britain]; enalapril [Hungary, Switzerland]; lisinopril [Malaysia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency ranges include data from hypertension and heart failure trials. Higher rates of adverse reactions have generally been noted in patients with CHF. However, the frequency of adverse effects associated with placebo is also increased in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (3%), chest pain (2%), first-dose hypotension (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (4% to 8%), headache (2% to 6%), fatigue (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting/nausea (1% to 2%), diarrhea (1.7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgias (2% to 5%), back pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN/serum creatinine increased (2%, transient elevations may occur with a higher frequency), worsening of renal function (in patients with bilateral renal artery stenosis or hypovolemia)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory symptoms, cough (2% to 4%; up to 13% in some studies), dyspnea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, agranulocytosis, alopecia, amblyopia, anaphylactoid reaction, angina, angioedema, arrhythmia, cerebrovascular accident, depression, dermatopolymyositis, eosinophilic pneumonitis, exfoliative dermatitis, gastrointestinal hemorrhage, heart failure, hemolytic anemia, hepatitis, hyperkalemia, hypertensive crisis, impotence, insomnia, MI, orthostatic hypotension, pancreatitis, pemphigus, photosensitivity, shock, stroke, syncope, thrombocytopenia, viral infection, visual hallucinations (Doane, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     A syndrome which may include fever, myalgia, arthralgia, interstitial nephritis, vasculitis, rash, eosinophilia and positive ANA, and elevated ESR has been reported with ACE inhibitors. In addition, pancreatitis, hepatic necrosis, neutropenia, and/or agranulocytosis (particularly in patients with collagen-vascular disease or renal impairment) have been associated with many ACE inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     U.S. labeling: Hypersensitivity to quinapril or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to quinapril or any component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus (type 1 or 2) or with moderate-to-severe renal impairment (GFR &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ); women who are pregnant, intend to become pregnant, or of childbearing potential and not using adequate contraception; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration:  May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Quinapril may decrease the serum concentration of Quinolone Antibiotics.  Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Quinapril may decrease the serum concentration of Tetracycline Derivatives.  Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F216347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effects of quinapril (eg, shepherd's purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Quinapril crosses the placenta; teratogenic effects may occur following maternal use during pregnancy. Drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Their use in pregnancy is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. Chronic maternal hypertension itself is also associated with adverse events in the fetus/infant. ACE inhibitors are not recommended during pregnancy to treat maternal hypertension or heart failure. Use of an ACE inhibitor should also be avoided in any woman of reproductive age. Women who are planning a pregnancy should be considered for other medication options if an ACE inhibitor is currently prescribed or the ACE inhibitor should be discontinued as soon as possible once pregnancy is detected. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed to an ACE inhibitor",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6199387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Quinapril is excreted in breast milk. The manufacturer recommends that caution be exercised when administering quinapril to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F216334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Accupril Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (90): $233.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $233.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $233.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $233.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Quinapril HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (90): $110.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (90): $110.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $110.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $110.07",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4116334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; serum creatinine and potassium; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F216336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Accupril (AR, AU, BE, BO, BR, BZ, CN, CO, CR, DO, EC, GT, HK, HN, ID, KP, LU, MX, NI, NZ, PA, PE, PH, PK, PR, PY, SV, TH, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Accuprin (IT);",
"     </li>",
"     <li>",
"      Accupro (AT, BG, CH, CZ, DE, DK, EE, FI, GB, HU, IE, PL, RU, SE);",
"     </li>",
"     <li>",
"      Accupron (GR);",
"     </li>",
"     <li>",
"      Acequin (IT);",
"     </li>",
"     <li>",
"      Acquin (AU);",
"     </li>",
"     <li>",
"      Acuitel (AE, BH, CY, EG, FR, IL, IQ, IR, JO, KW, LB, LY, MU, OM, QA, SA, SY, TR, YE);",
"     </li>",
"     <li>",
"      Acupril (MX, NL, PT);",
"     </li>",
"     <li>",
"      Ectren (ES);",
"     </li>",
"     <li>",
"      Filpril (AU);",
"     </li>",
"     <li>",
"      Korec (FR);",
"     </li>",
"     <li>",
"      Lidaltrin (ES);",
"     </li>",
"     <li>",
"      Qpril (AU, NZ);",
"     </li>",
"     <li>",
"      Quinapro (IE);",
"     </li>",
"     <li>",
"      Quinaril (TH);",
"     </li>",
"     <li>",
"      Quinaspen (ZA);",
"     </li>",
"     <li>",
"      Quinazil (IT);",
"     </li>",
"     <li>",
"      Quinsil (TH);",
"     </li>",
"     <li>",
"      Quiprex (CO);",
"     </li>",
"     <li>",
"      Yiheng (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F216315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor; results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion; a CNS mechanism may also be involved in hypotensive effect as angiotensin II increases adrenergic outflow from CNS; vasoactive kallikreins may be decreased in conversion to active hormones by ACE inhibitors, thus reducing blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Quinapril: &ge;60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Quinapril: 97%; Quinaprilat: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapidly hydrolyzed to quinaprilat, the active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Quinapril: 0.8 hours; Quinaprilat: 3 hours; increases as Cl",
"     <sub>",
"      cr",
"     </sub>",
"     decreases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Quinapril: 1 hour; Quinaprilat: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (50% to 60% primarily as quinaprilat)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, &ldquo;Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(23):2981-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/12479763/pubmed\" id=\"12479763\" target=\"_blank\">",
"        12479763",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doane J and Stults B, &ldquo;Visual Hallucinations Related to Angiotensin-Converting Enzyme Inhibitor Use: Case Reports and Review,&rdquo;",
"      <i>",
"       J Clin Hypertens (Greenwich)",
"      </i>",
"      , 2013 [epub ahead pf print].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fox KM and EURopean Trial on Reduction of Cardiac Events With Perindopril in Stable Coronary Artery Disease Investigators, &ldquo;Efficacy of Perindopril in Reduction of Cardiovascular Events Among Patients With Stable Coronary Artery Disease: Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial (The EUROPA Study),&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):782-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/13678872/pubmed\" id=\"13678872\" target=\"_blank\">",
"        13678872",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114 (2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al, &ldquo;Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 100(23):2312-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/10587334/pubmed\" id=\"10587334\" target=\"_blank\">",
"        10587334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, Greaves SC, Arnold JM, et al, &ldquo;Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction. The Healing and Early Afterload Reducing Therapy Trial,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(12):2643-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/9193433/pubmed\" id=\"9193433\" target=\"_blank\">",
"        9193433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yusuf S, Sleight P, Pogue J, et al, &ldquo;Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. The Heart Outcomes Prevention Evaluation Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(3):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/29/24024/abstract-text/10639539/pubmed\" id=\"10639539\" target=\"_blank\">",
"        10639539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9843 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.236-1521AB7FD8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24024=[""].join("\n");
var outline_f23_29_24024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709380\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216351\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216352\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216392\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216356\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4476059\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216357\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216358\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216359\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216326\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216312\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216329\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216388\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216400\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216390\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216332\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216316\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299972\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216321\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216347\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216323\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216335\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216362\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6199387\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216334\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4116334\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216336\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216315\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216331\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9843|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/24/15749?source=related_link\">",
"      Quinapril: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/24/42375?source=related_link\">",
"      Quinapril: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_29_24025="Electrophysiologic evaluation of arrhythmias associated with the Wolff-Parkinson-White syndrome";
var content_f23_29_24025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Electrophysiologic evaluation of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24025/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24025/contributors\">",
"     David J Callans, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24025/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24025/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24025/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/29/24025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 17, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wolff-Parkinson-White (WPW) syndrome is characterized by episodes of tachycardia due to an accessory atrioventricular pathway. Tachycardias associated with WPW syndrome can be classified into those in which the accessory pathway is necessary for initiation and maintenance of the tachycardia (eg, atrioventricular reentrant tachycardia), and those in which the bypass tract acts as a \"bystander,\" providing a route of conduction from the anatomic site of tachycardia origin to other regions of the heart (eg, atrial fibrillation and atrial flutter) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accessory pathway depends upon the rapid inward sodium current for the action potential and, as is characteristic of such \"fast\" response tissues, may conduct rapidly and, because of its short refractory period, may recover its excitability rapidly. Some accessory pathways can conduct atrial flutter 1:1 to the ventricles, resulting in a rate of approximately 300",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    Atrial fibrillation may conduct even more rapidly, possibly degenerating into ventricular fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link&amp;anchor=H8471569#H8471569\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\", section on 'Ventricular fibrillation and sudden death'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the electrophysiologic evaluation of the arrhythmias associated with the WPW syndrome to guide both pharmacologic and nonpharmacologic therapy. The electrophysiologic characteristics of the accessory pathways, as well as the technique of electrophysiologic mapping and its application to WPW, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27305?source=see_link\">",
"     \"Electrophysiologic cardiac mapping: Use in specific arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION OF AV ACCESSORY PATHWAY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiologic evaluation of accessory pathway function can be performed in both sinus rhythm and during atrial and ventricular pacing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     In sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;During preexcited sinus rhythm, the HV interval is abnormally short and the QRS duration prolonged. Although the AH interval is generally normal, the PR and AV intervals are also shortened to an extent that is equal to the degree of HV interval abbreviation. With increasing preexcitation, the HV interval shortens progressively and may achieve negative values while the QRS duration lengthens and the PR and AV intervals remain constant. During complete preexcitation, the His bundle potential is often overlapped and masked by the larger amplitude of the local ventricular electrogram.",
"   </p>",
"   <p>",
"    Analysis of the totally preexcited QRS morphology and corresponding electrograms recorded from the AV groove is invaluable for localizing the ventricular insertion of the AV accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, this technique can result in erroneous conclusions when multiple bypass tracts, preexisting intraventricular conduction delay, hypertrophy, drug effects, electrolyte imbalance,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myocardial infarction are present [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2\">",
"     2",
"    </a>",
"    ]. Pacing from the right and left atria, noting the site of stimulation that yields the shortest stimulus to the delta wave interval, is also useful [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Body surface isopotential mapping is another approach for noninvasive localization of the ventricular insertion of bypass tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     During atrial and ventricular pacing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of VA conduction and the retrograde atrial activation sequence help identify the atrial insertion point of an accessory pathway. This should ideally be performed during orthodromic atrioventricular reentrant tachycardia (AVRT) since the accessory pathway serves as the sole route for retrograde conduction into the atria. Ventricular pacing and extrastimulation can also be used to assess retrograde VA conduction, provided that retrograde AV nodal conduction is not present during these maneuvers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increasing the ventricular pacing rate or delivering ventricular extrastimuli can be used to accentuate accessory pathway retrograde conduction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system manifests decremental retrograde conduction (ie, slowed conduction at faster rates). As a result, there is a progressive delay in VA conduction as the ventricular pacing rate increases, and ultimately complete block develops when the refractory period of the AV node is reached. Retrograde VA conduction over the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system during ventricular pacing results in a normal sequence of retrograde atrial activation; the atrial electrogram recorded by the His bundle catheter is inscribed first, followed by centrifugal spread of atrial activation from that point [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, most AV accessory pathways conduct retrogradely in a nondecremental manner (ie, the VA conduction time over the accessory pathway remains constant at all ventricular pacing rates and extrastimulus coupling intervals until the refractory period is reached and complete retrograde block occurs).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Left- and right-sided accessory pathways activate the atria in an eccentric fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. The atrial insertion of an AV bypass tract should be sought by analyzing atrial electrograms recorded directly from a catheter placed on the tricuspid annulus and indirectly from the mitral annulus via the coronary sinus during AVRT and ventricular pacing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extrastimulation (",
"    <a class=\"graphic graphic_figure graphicRef77941 \" href=\"UTD.htm?21/50/22319\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Atrial and ventricular pacing should be performed at increasing rates until loss of 1:1 antegrade or retrograde conduction occurs within both the normal AV conduction system and the accessory pathway. In addition to inducing orthodromic AVRT, these maneuvers permit identification of the \"weak\" and \"strong\" limbs of the circuit responsible for AVRT as well as determining the ability of the AV bypass tract to mediate a rapid ventricular response during atrial fibrillation (AF) and atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. The antegrade or retrograde limb having the greater difference between the clinical tachycardia cycle length and the paced cycle length causing block in that pathway can be considered the \"strong\" limb of conduction, while the limb having the smaller difference can be considered the \"weak\" limb. In other words, the weak limb can be blocked at longer paced cycle lengths (ie, slower heart rates) because it has a longer refractory period",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more tenuous conduction properties. Pharmacologic therapy of arrhythmia associated with preexcitation syndromes is generally aimed at the weak limb. A major limitation to this strategy is the influence of circulating catecholamines on both accessory pathway and AV nodal conduction. This can unpredictably improve the function of the presumed \"weak\" limb, and thwart attempts at pharmacologic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=see_link\">",
"     \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial pacing should be performed as close as possible to the atrial insertion of the AV bypass tract [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2\">",
"     2",
"    </a>",
"    ]. Ventricular pacing is generally performed at the right ventricular apex (RVA); however, conduction time from the RVA to the ventricular insertion of the accessory pathway should be taken into consideration when analyzing the response to ventricular pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antegrade and retrograde accessory pathway refractory periods should also be measured as close as possible to the bypass tract using the extrastimulus technique in the atria and ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2\">",
"     2",
"    </a>",
"    ]. The extrastimulus should be delivered in 10 to 20 msec decrements until the refractory period at the site of extrastimulus delivery is reached.",
"   </p>",
"   <p>",
"    Bypass tracts that maintain 1:1 retrograde conduction when the ventricular paced cycle lengths are &le;300 msec may mediate a rapid orthodromic AVRT. Similarly, the minimum atrial paced cycle length during which 1:1 preexcited ventricular conduction is maintained and the antegrade refractory period of the bypass tract are strongly correlated with the shortest preexcited RR interval and mean RR interval during AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2,15,16\">",
"     2,15,16",
"    </a>",
"    ]. However, the best measure of the ability of an accessory pathway to mediate a rapid ventricular rate response during AF is to measure the mean ventricular rate and shortest preexcited RR interval after the induction of AF in the laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Detection of multiple accessory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some WPW syndrome patients have multiple accessory pathways. Although early series suggested that the incidence of multiple pathways was as high as 10 percent, subsequent experience suggests that this phenomenon is less common [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2,17-19\">",
"     2,17-19",
"    </a>",
"    ]. The presence of multiple pathways was very problematic during the days of surgical ablation, as intraprocedural mapping was limited during surgery. Even with contemporary electrophysiologic mapping techniques, the detection of multiple accessory pathways can be a challenging task (",
"    <a class=\"graphic graphic_figure graphicRef71684 \" href=\"UTD.htm?25/9/25749\">",
"     figure 2",
"    </a>",
"    ). Helpful diagnostic clues include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of more than one preexcited QRS morphology during sinus rhythm, incremental atrial pacing, or atrial fibrillation (AF) (",
"      <a class=\"graphic graphic_waveform graphicRef71133 \" href=\"UTD.htm?36/31/37370\">",
"       waveform 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Changing retrograde P wave morphologies, atrial electrograms, and atrial activation patterns during orthodromic AVRT",
"     </li>",
"     <li>",
"      Discordance of more than 1 to 2 cm between atrial and ventricular bypass tract insertion points mapped during orthodromic AVRT and antidromic AVRT",
"     </li>",
"     <li>",
"      Spontaneous change between orthodromic AVRT and antidromic AVRT or between two antidromic AVRTs having different preexcited QRS patterns",
"     </li>",
"     <li>",
"      Abrupt change in preexcited QRS configuration during atrial extrastimulation, incremental pacing, or after antiarrhythmic drug administration, a reflection of differing refractory periods of the bypass tracts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Use of adjunctive interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional interventions may be helpful in the evaluation of the patient with WPW:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"       isoproterenol",
"      </a>",
"      during electrophysiologic study can unmask potentially dangerous catecholamine facilitation of accessory pathway function [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiarrhythmic drugs have been used as a noninvasive screening test to assess an accessory pathway's propensity to mediate a rapid ventricular response during atrial fibrillation (AF). In one study, an intravenous dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      (or ajmaline) that caused complete loss of preexcitation had good positive predictive value for identifying bypass tracts with relatively long antegrade refractory periods(&gt;270 msec) and a low risk for a rapid ventricular response during AF [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2,22\">",
"       2,22",
"      </a>",
"      ]. However, the continued presence of preexcitation during drug infusion does not predict a pathway with a short refractory period (&lt;250 msec) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Adenosine transiently depresses AV nodal conduction but has no effect on accessory pathways that conduct non-decrementally (decremental conduction is the decreasing speed of conduction until some but not all beats are transmitted through the AV nodal tissue). Administration of adenosine during electrophysiologic study or ECG monitoring is therefore useful in transiently unmasking preexcitation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/26\">",
"       26",
"      </a>",
"      ]. Caution must be used when using adenosine since it may increase the susceptibility to AF and orthodromic AVRT and may promote incessant orthodromic AVRT [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/27-29\">",
"       27-29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exercise uncommonly causes an abrupt loss of preexcitation as the sinus rate increases (",
"      <a class=\"graphic graphic_waveform graphicRef76833 \" href=\"UTD.htm?13/9/13463\">",
"       waveform 2",
"      </a>",
"      ). This is a reassuring, but not absolute, indicator that the accessory pathway is unlikely to conduct AF with a rapid ventricular response. More often, preexcitation becomes inapparent because increasing sympathetic and decreasing vagal tone enhance AV nodal conduction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ATRIOVENTRICULAR REENTRANT TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major forms of AVRT, orthodromic and antidromic, which can be differentiated in part by the findings on the electrocardiogram:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the tachycardia has a narrow QRS complex (orthodromic AVRT), the antegrade limb (ie, the pathway that conducts the impulse to the ventricle) is the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system; in this setting, the delta wave seen during sinus rhythm is lost since antegrade conduction is not via the accessory pathway (ie, the ventricle is not preexcited) (",
"      <a class=\"graphic graphic_figure graphicRef71302 \" href=\"UTD.htm?15/35/15926\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef54720 \" href=\"UTD.htm?28/50/29478\">",
"       waveform 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef77095 \" href=\"UTD.htm?17/16/17670\">",
"       waveform 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If the tachycardia has a wide QRS complex (antidromic AVRT), the antegrade limb is usually the accessory pathway (",
"      <a class=\"graphic graphic_figure graphicRef50433 \" href=\"UTD.htm?34/52/35655\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef71410 \" href=\"UTD.htm?43/2/44072\">",
"       waveform 5",
"      </a>",
"      ). An orthodromic AVRT may be associated with a wide QRS complex in the presence of a preexisting or rate-related functional bundle branch block.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Orthodromic AVRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthodromic AVRT comprises 95 percent of the reentrant tachycardias associated with the WPW syndrome (",
"    <a class=\"graphic graphic_figure graphicRef71302 \" href=\"UTD.htm?15/35/15926\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef54720 \" href=\"UTD.htm?28/50/29478\">",
"     waveform 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef77095 \" href=\"UTD.htm?17/16/17670\">",
"     waveform 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Because orthodromic AVRT incorporates the entire heart within its macroreentrant circuit, tachycardia initiation, termination, and perturbation are easily invoked by spontaneous or induced atrial or ventricular premature beats (APBs or VPBs) or rapid atrial and ventricular pacing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An APB that induces orthodromic AVRT is conducted with an increased AH interval compared with the AH intervals during the preceding atrial drive train, reflecting decremental or delayed conduction within the AV node. The QRS complexes of the tachycardia that follows the APB are not preexcited and usually have normal HV intervals and QRS durations (",
"      <a class=\"graphic graphic_waveform graphicRef81938 \" href=\"UTD.htm?31/52/32585\">",
"       waveform 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef59861 \" href=\"UTD.htm?11/43/11954\">",
"       waveform 7",
"      </a>",
"      ). Not uncommonly, the initial QRS complexes are prolonged, reflecting aberrant conduction within the His-Purkinje system. Following the first normal or non-preexcited QRS complex, retrograde atrial activation occurs in a pattern reflecting the site of atrial insertion of the bypass tract. Initiation of orthodromic AVRT in the presence of a concealed accessory pathway follows the same rules except that preexcitation is not present during the preceding atrial drive train or sinus rhythm (",
"      <a class=\"graphic graphic_waveform graphicRef77095 \" href=\"UTD.htm?17/16/17670\">",
"       waveform 4",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10853?source=see_link\">",
"       \"Concealed accessory pathways\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      When a VPB induces orthodromic AVRT, the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system must have a longer retrograde refractory period than the AV accessory pathway. The VPB that induces the tachycardia is conducted retrogradely and activates the atria in a pattern consistent with the atrial insertion point of the accessory pathway. A non-preexcited QRS complex then follows as a result of antegrade AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system conduction.",
"     </li>",
"     <li>",
"      The relationship and timing of atrial and ventricular activation are important diagnostic features of orthodromic AVRT. Since the atria and ventricles are part of a macroreentrant circuit and have a 1:1 relationship with each other, observing AV dissociation or intermittent AV block during a tachycardia",
"      <strong>",
"       excludes",
"      </strong>",
"      an AVRT (",
"      <a class=\"graphic graphic_waveform graphicRef59861 \" href=\"UTD.htm?11/43/11954\">",
"       waveform 7",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"       \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spontaneous or induced functional bundle branch block occurring during orthodromic AVRT is a diagnostically useful phenomenon. If bundle branch block exists ipsilateral to a free wall bypass tract, the reentrant impulse is compelled to traverse a greater distance from the ventricular insertion of the conducting His-Purkinje fibers to the ventricular insertion of the bypass tract. As a result, the global VA time interval during the tachycardia must increase, usually by at least 35 msec; the tachycardia cycle length also may increase (",
"      <a class=\"graphic graphic_figure graphicRef51093 \" href=\"UTD.htm?35/49/36628\">",
"       figure 5",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/31\">",
"       31",
"      </a>",
"      ]. In one study of 95 patients, for example, an increase in the VA time interval by &ge;40 msec in the absence of fascicular block had a sensitivity and specificity of 95 and 100 percent, respectively, for the presence of a free wall bypass tract [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/32\">",
"       32",
"      </a>",
"      ]. However, little or no change of the tachycardia cycle length may occur if there is a corresponding decrease in the AH interval [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/23,30\">",
"       23,30",
"      </a>",
"      ]. In contrast, bundle branch block occurring contralateral to a free wall AV accessory pathway has no effect on the VA interval and the tachycardia cycle length.",
"     </li>",
"     <li>",
"      During orthodromic AVRT, the ability to reset the tachycardia by advancing the next atrial activation with a properly timed VPB, the next ventricular activation with an APB, or the next tachycardia cycle with either an APB or a VPB indicates that the entire heart is involved in the tachycardia circuit (",
"      <a class=\"graphic graphic_figure graphicRef82614 \" href=\"UTD.htm?1/19/1335\">",
"       figure 6",
"      </a>",
"      ). Furthermore, a VPB delivered late in the diastolic interval of orthodromic AVRT, when the His bundle is refractory, that advances the next set of atrial electrograms without altering the retrograde atrial activation pattern proves that a bypass tract is present and is participating in the tachycardia; retrograde conduction of the VPB can occur only over an accessory pathway because the His bundle is still refractory [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Termination of orthodromic AVRT results when block occurs within either the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system or the accessory pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. An APB conducted in an orthodromic direction (ie, to the ventricle via the AV node) usually terminates the tachycardia by blocking antegradely within the AV node. Alternatively, an APB conducted in an antidromic direction (ie, to the ventricle via the accessory pathway) collides with the retrograde tachycardia impulse, usually within the atria or bypass tract.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tachycardia termination by a VPB usually occurs when it is conducted to the ventricle via the accessory pathway and blocks within this tract, rendering it refractory to the next impulse (",
"    <a class=\"graphic graphic_waveform graphicRef81938 \" href=\"UTD.htm?31/52/32585\">",
"     waveform 6",
"    </a>",
"    ). Alternatively, the VPB may enter the AV",
"    <span class=\"nowrap\">",
"     node/His-Purkinje",
"    </span>",
"    system in a retrograde direction and collide with the antegrade tachycardia impulse within the AV",
"    <span class=\"nowrap\">",
"     node/His-Purkinje",
"    </span>",
"    system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous tachycardia termination after a retrograde P wave on the surface ECG and an atrial electrogram not followed by a His bundle potential on the intracardiac recording indicates that block occurred within the AV node. On the other hand, tachycardia termination after a QRS complex and ventricular electrogram not followed by a retrograde P wave and atrial electrogram implies that block occurred within the bypass tract [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most instances, spontaneous block occurs within the AV node. Cycle length alternans may be seen immediately preceding AV nodal block and tachycardia termination, during which long-to-short oscillations occur in the tachycardia cycle length and AH interval, while the HV and VA intervals remain constant.",
"   </p>",
"   <p>",
"    Spontaneous block occurring within the AV bypass tract is uncommonly observed during very rapid orthodromic AVRT. However, accessory pathways that exhibit slow, decremental retrograde conduction may be the site of block and tachycardia termination following the same autonomic and pharmacologic perturbations that affect the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antidromic AVRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antidromic AVRT is the least common arrhythmia associated with WPW syndrome, occurring in only 5 to 10 percent of patients (",
"    <a class=\"graphic graphic_figure graphicRef50433 \" href=\"UTD.htm?34/52/35655\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef71410 \" href=\"UTD.htm?43/2/44072\">",
"     waveform 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1,38,39\">",
"     1,38,39",
"    </a>",
"    ]. The tachycardia is characterized by a wide QRS complex that is fully preexcited, usually regular RR intervals, and ventricular rates of up to 250",
"    <span class=\"nowrap\">",
"     beats/min.",
"    </span>",
"    Antidromic AVRT can result in considerable diagnostic and therapeutic uncertainty because the differential diagnosis includes all other wide QRS tachycardias, such as ventricular tachycardia, any supraventricular tachycardia (SVT) which is conducted aberrantly, and tachycardias of atrial and junctional origin that use the accessory pathway for activation of the ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some patients with antidromic AVRT, preexcitation may not be apparent in sinus rhythm because they have a left-sided bypass tract as the antegrade route for conduction. In this setting, the time for the atrial impulse to reach the atrial insertion of the accessory pathway is longer than the time to reach the AV node (",
"    <a class=\"graphic graphic_waveform graphicRef80663 \" href=\"UTD.htm?24/45/25296\">",
"     waveform 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Demonstrating a preexcited QRS morphology that is identical during antidromic AVRT and atrial pacing near the atrial insertion of the accessory pathway is diagnostically helpful if additional antegrade-conducting accessory pathways are not present [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. However, the prevalence of multiple accessory pathways in patients who experience antidromic AVRT may range from 33 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1,2,5,18,38\">",
"     1,2,5,18,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrophysiology testing can reveal a number of other findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If only one antegrade-conducting AV accessory pathway exists, the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system must be the route for retrograde atrial activation during antidromic AVRT. During tachycardia, the earliest retrograde atrial activation is inscribed at the His bundle recording site; the sequence of retrograde atrial activation is normal and identical to that during ventricular pacing.",
"     </li>",
"     <li>",
"      A 1:1 VA conduction relationship exists since there is obligatory participation of the atria and ventricles in the reentrant circuit.",
"     </li>",
"     <li>",
"      Atrial and ventricular extrastimuli will advance the next set of ventricular and atrial electrograms, respectively, as well as the entire tachycardia cycle, while preserving the tachycardia electrogram activation sequence since the atria and ventricles are necessary for tachycardia maintenance.",
"     </li>",
"     <li>",
"      The HV interval is negative with a retrograde His potential either immediately preceding the local ventricular electrogram of the His bundle recording or, alternatively, occurring simultaneously with and obscured by the larger amplitude ventricular electrogram [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As with orthodromic AVRT, tachycardia termination can occur following properly timed atrial and ventricular extrastimuli or spontaneously when block occurs within either the accessory pathway or the AV",
"      <span class=\"nowrap\">",
"       node/His-Purkinje",
"      </span>",
"      system [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2,38,39\">",
"       2,38,39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PERMANENT JUNCTIONAL RECIPROCATING TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent or incessant junctional reciprocating (or reentrant) tachycardia (PJRT) is a form of orthodromic AVRT resulting from an accessory pathway with slow and decremental conduction properties. PJRT occurs at rates between 120 and 200",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    and the QRS duration is usually normal (",
"    <a class=\"graphic graphic_waveform graphicRef67767 \" href=\"UTD.htm?25/13/25814\">",
"     waveform 9",
"    </a>",
"    ). Features which distinguish PJRT from other tachyarrhythmias in WPW syndrome patients include its tendency for incessant behavior and the",
"    <span class=\"nowrap\">",
"     QRS/P",
"    </span>",
"    wave relationship (ie, a long RP and short PR) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1,40,41\">",
"     1,40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reason for the incessant nature of PJRT is not clear. Its onset and rate are quite sensitive to changes in autonomic tone and prior sinus rhythm rate. Spontaneous PJRT initiation during electrophysiologic testing often occurs after only trivial increases in the rate of sinus rhythm or atrial overdrive pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the accessory pathway is anatomically separate from the AV",
"    <span class=\"nowrap\">",
"     node/His-Purkinje",
"    </span>",
"    system, a ventricular extrastimulus delivered late in diastole when the His bundle is refractory can easily reset the next atrial activation and tachycardia cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. This response cannot occur during uncommon \"fast-slow\" AV nodal reentrant tachycardia or atrial tachycardia and is useful for differentiating among these three forms of a \"long R-P\" SVT [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .) Because the accessory pathway conducts decrementally during PJRT, the atrial and tachycardia cycle reset response to the VPB may actually be one of delayed activation, rather than advancement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tachycardia termination occurring spontaneously or following vagomimetic maneuvers frequently results from block in the accessory pathway; the ECG and intracardiac recordings show the last tachycardia event as a QRS complex and ventricular electrogram without a subsequent P wave and atrial electrogram.",
"   </p>",
"   <p>",
"    Chronic suppression of PJRT is usually not possible with drugs, and ablation of the accessory pathway is often necessary to achieve arrhythmia control [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1,41-43\">",
"     1,41-43",
"    </a>",
"    ]. PJRT frequently occurs in infants and children, and its incessant behavior may result in dilated cardiomyopathy and congestive heart failure; these changes are potentially reversible if the accessory pathway can be successfully ablated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1,41,44\">",
"     1,41,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ATRIAL FIBRILLATION AND ATRIAL FLUTTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is the index arrhythmia in up to 20 percent of patients with WPW syndrome (",
"    <a class=\"graphic graphic_waveform graphicRef60790 \" href=\"UTD.htm?41/16/42250\">",
"     waveform 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef75523 \" href=\"UTD.htm?42/59/43962\">",
"     waveform 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef71133 \" href=\"UTD.htm?36/31/37370\">",
"     waveform 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2,45-47\">",
"     2,45-47",
"    </a>",
"    ]. AF is usually intermittent rather than persistent or permanent. Patients with bypass tracts causing overt preexcitation seem to be more prone to AF than those whose bypass tracts are concealed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2\">",
"     2",
"    </a>",
"    ]. The ability of the accessory pathway to mediate a rapid and hemodynamically unstable preexcited ventricular response during AF may lead to sudden death due to ventricular fibrillation (VF) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1,48\">",
"     1,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10853?source=see_link\">",
"     \"Concealed accessory pathways\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VF resulting from AF is rare as the presenting arrhythmia in an individual not previously known to have WPW syndrome. In one study of 690 patients with WPW, aborted sudden death as the first symptomatic arrhythmia occurred in only one percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/48\">",
"     48",
"    </a>",
"    ]. The majority of patients with WPW syndrome who have AF have had preexisting episodes of AVRT. It is widely thought that most episodes of VF develop from degeneration of rapid orthodromic AVRT, particularly in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial flutter (both intermittent and persistent) is less common than paroxysmal AF in WPW syndrome (",
"    <a class=\"graphic graphic_figure graphicRef78602 \" href=\"UTD.htm?41/63/43002\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/1\">",
"     1",
"    </a>",
"    ]. This may result from the low incidence of associated structural heart disease in patients with the WPW syndrome.",
"   </p>",
"   <p>",
"    The atrial electrograms recorded during preexcited AF are not different in appearance from those recorded in the absence of preexcitation. The ventricular rate during preexcited AF can vary considerably due to the important rate-modulating effects of autonomic tone and the interplay between refractoriness and conduction in the AV",
"    <span class=\"nowrap\">",
"     node/His-Purkinje",
"    </span>",
"    system versus the bypass tract.",
"   </p>",
"   <p>",
"    Repetitive concealed conduction into the bypass tract during preexcited AF may result in a slower ventricular response than predicted on the basis of the antegrade refractory period of the accessory pathway and shortest atrial pacing cycle length maintaining 1:1 preexcited conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2\">",
"     2",
"    </a>",
"    ]. These factors also influence the degree to which QRS complexes will be preexcited based upon the extent of fusion between normal and preexcited complexes. Detection of more than one preexcited QRS morphology during AF suggests the presence of multiple AV bypass tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The total absence of preexcited QRS complexes during AF despite the presence of persistent or intermittent preexcitation during sinus rhythm is a reassuring sign that the antegrade refractory period of the bypass tract is long and the pathway unlikely to mediate a rapid ventricular response during spontaneous AF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ASYMPTOMATIC PATIENTS WITH A WPW ECG PATTERN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with a WPW pattern on the electrocardiogram are asymptomatic or have only an occasional tachyarrhythmia that is not associated with significant symptoms. Most asymptomatic patients remain asymptomatic and up to 30 percent lose antegrade accessory pathway conduction and evidence for ventricular preexcitation. The incidence of sudden cardiac death in such patients is very low and some studies found no cases of sudden cardiac death in truly asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Older reports suggested that asymptomatic patients do not generally require electrophysiologic testing or therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/52\">",
"     52",
"    </a>",
"    ]. However, subsequent series have provided conflicting data on the value of electrophysiologic testing in such cases.",
"   </p>",
"   <p>",
"    One study evaluated 75 asymptomatic patients who underwent a baseline electrophysiologic study and were followed for a mean of 4.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/50\">",
"     50",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      No patient experienced sudden cardiac death and nine (12 percent) lost ECG evidence of preexcitation (ie, the delta wave disappeared).",
"     </li>",
"     <li>",
"      Symptomatic AVRT developed in six patients (8 percent) but not in any of those with absent retrograde accessory pathway conduction.",
"     </li>",
"     <li>",
"      Inducible arrhythmia did not predict an arrhythmic event during follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a larger series of 162 asymptomatic patients found that the 29 percent who had inducible arrhythmias (17 atrial fibrillation, 19 atrioventricular reciprocating tachycardia (AVRT), and 11 AVRT degenerating into AF) were at increased risk for a symptomatic event [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24025/abstract/53\">",
"     53",
"    </a>",
"    ]. At a mean follow-up of three years, several observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thirty-three patients (20 percent) developed symptomatic arrhythmias. These patients were, on average, younger than those who did not (20 versus 37 years).",
"     </li>",
"     <li>",
"      A subsequent symptomatic tachyarrhythmia was much more common in the patients with inducible arrhythmia (62 versus three percent, adjusted odds ratio 17.9, 95% CI 3.85 to 83.26).",
"     </li>",
"     <li>",
"      Three patients developed ventricular fibrillation (VF); all were inducible and all experienced symptomatic AF prior to developing VF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Radiofrequency ablation reduces the risk of arrhythmic events in young patients with asymptomatic WPW who have inducible arrhythmias. This approach is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=see_link&amp;anchor=H5#H5\">",
"     \"Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\", section on 'Asymptomatic patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3190726\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wolff-Parkinson-White (WPW) syndrome is characterized by episodes of tachycardia due to an accessory atrioventricular pathway.",
"     </li>",
"     <li>",
"      The accessory pathway (ie, bypass tract) present in patients with WPW syndrome may participate in several different tachycardias:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Orthodromic atrioventricular reciprocating tachycardia (AVRT), with antegrade conduction through the AV node and retrograde conduction via the bypass tract. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Orthodromic AVRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antidromic AVRT, with antegrade conduction through the bypass tract and retrograde conduction via the AV node. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antidromic AVRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preexcited tachycardias (eg, atrial fibrillation, atrial flutter), where the bypass tract is a bystander that conducts the tachycardia to the ventricles. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Atrial fibrillation and atrial flutter'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful electrophysiologic study can detect the presence and location of a bypass tract, exclude the presence of multiple bypass tracts, and yield some information about the likelihood of extremely rapid antegrade conduction and attendant risk. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation of AV accessory pathway function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrial and ventricular stimulation during tachycardia (particularly the delivery of His synchronous ventricular extrastimuli) is essential for ruling in or excluding participation of a bypass tract in a tachycardia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation of AV accessory pathway function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid bypass tract conduction during atrial fibrillation can result in ventricular fibrillation and sudden death. This is unusual, and typically is preceded by prior symptomatic episodes of orthodromic supraventricular tachycardia. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Atrial fibrillation and atrial flutter'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Yee, R, Klein, GJ, Sharma, AD, et, al. Tachycardia associated with accessory atrioventricular pathways. In: Cardiac Electrophysiology, Zipes, DP, Jalife, J (Eds), WB Saunders, Philadelphia 1990. p.463.",
"    </li>",
"    <li>",
"     Josephson ME. Preexcitation Syndromes. In: Clinical Cardiac Electrophysiology, Lea &amp; Febiger, Philadelphia 1993. p.311.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/3\">",
"      Cain ME, Luke RA, Lindsay BD. Diagnosis and localization of accessory pathways. Pacing Clin Electrophysiol 1992; 15:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/4\">",
"      Gallagher JJ, Pritchett EL, Sealy WC, et al. The preexcitation syndromes. Prog Cardiovasc Dis 1978; 20:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/5\">",
"      Denes P, Wyndham CR, Amat-y-Leon F, et al. Atrial pacing at multiple sites in the Wolff-Parkinson-White syndrome. Br Heart J 1977; 39:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/6\">",
"      Benson, WD, Sterba, R, Gallagher, JJ, et al. Localization of the site of ventricular pre-excitation with body surface maps in patients with Wolff-Parkinson-White syndrome. Circulation 1982; 65:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/7\">",
"      Kamakura S, Shimomura K, Ohe T, et al. The role of initial minimum potentials on body surface maps in predicting the site of accessory pathways in patients with Wolff-Parkinson-White syndrome. Circulation 1986; 74:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/8\">",
"      Liebman J, Zeno JA, Olshansky B, et al. Electrocardiographic body surface potential mapping in the Wolff-Parkinson-White syndrome. Noninvasive determination of the ventricular insertion sites of accessory atrioventricular connections. Circulation 1991; 83:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/9\">",
"      Dubuc M, Nadeau R, Tremblay G, et al. Pace mapping using body surface potential maps to guide catheter ablation of accessory pathways in patients with Wolff-Parkinson-White syndrome. Circulation 1993; 87:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/10\">",
"      Josephson ME, Scharf DL, Kastor JA, Kitchen JG. Atrial endocardial activation in man. Electrode catheter technique of endocardial mapping. Am J Cardiol 1977; 39:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/11\">",
"      Amat-y-Leon F, Dhingra RC, Wu D, et al. Catheter mapping of retrograde atrial activation. Observations during ventricular pacing and AV nodal re-entrant paroxysmal tachycardia. Br Heart J 1976; 38:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/12\">",
"      Gallagher JJ, Sealy WC, Kasell J, Wallace AG. Multiple accessory pathways in patients with the pre-excitation syndrome. Circulation 1976; 54:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/13\">",
"      Jackman WM, Friday KJ, Fitzgerald DM, et al. Use of intracardiac recordings to determine the site of drug action in paroxysmal supraventricular tachycardia. Am J Cardiol 1988; 62:8L.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/14\">",
"      Benditt DG, Benson DW Jr, Dunnigan A, et al. Role of extrastimulus site and tachycardia cycle length in inducibility of atrial preexcitation by premature ventricular stimulation during reciprocating tachycardia. Am J Cardiol 1987; 60:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/15\">",
"      Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 1979; 301:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/16\">",
"      Wellens, HJJ, Durrer, D. Relation between refractory period of the accessory pathway and ventricular frequency during atrial fibrillation in patients with the Wolff-Parkinson-White syndrome. Am J Cardiol 1974; 33:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/17\">",
"      Fananapazir L, German LD, Gallagher JJ, et al. Importance of preexcited QRS morphology during induced atrial fibrillation to the diagnosis and localization of multiple accessory pathways. Circulation 1990; 81:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/18\">",
"      Milstein S, Sharma AD, Guiraudon GM, Klein GJ. An algorithm for the electrocardiographic localization of accessory pathways in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol 1987; 10:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/19\">",
"      Colavita PG, Packer DL, Pressley JC, et al. Frequency, diagnosis and clinical characteristics of patients with multiple accessory atrioventricular pathways. Am J Cardiol 1987; 59:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/20\">",
"      Wellens HJ, Brugada P, Roy D, et al. Effect of isoproterenol on the anterograde refractory period of the accessory pathway in patients with the Wolff-Parkinson-White syndrome. Am J Cardiol 1982; 50:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/21\">",
"      Helmy I, Scheinman MM, Herre JM, et al. Electrophysiologic effects of isoproterenol in patients with atrioventricular reentrant tachycardia treated with flecainide. J Am Coll Cardiol 1990; 16:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/22\">",
"      Wellens HJ, Braat S, Brugada P, et al. Use of procainamide in patients with the Wolff-Parkinson-White syndrome to disclose a short refractory period of the accessory pathway. Am J Cardiol 1982; 50:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/23\">",
"      Critelli G, Gallagher JJ, Perticone F, et al. Evaluation of noninvasive tests for identifying patients with preexcitation syndrome at risk of rapid ventricular response. Am Heart J 1984; 108:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/24\">",
"      Wellens HJ, B&auml;r FW, Dassen WR, et al. Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway. Am J Cardiol 1980; 46:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/25\">",
"      Fananapazir L, Packer DL, German LD, et al. Procainamide infusion test: inability to identify patients with Wolff-Parkinson-White syndrome who are potentially at risk of sudden death. Circulation 1988; 77:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/26\">",
"      Walker KW, McAnulty JH, Kron J, et al. Unmasking accessory pathway conduction with adenosine-induced atrioventricular nodal block after radiofrequency catheter ablation. Chest 1993; 104:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/27\">",
"      Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989; 32:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/28\">",
"      Dougherty AH, Gilman JK, Wiggins S, et al. Provocation of atrioventricular reentry tachycardia: a paradoxical effect of adenosine. Pacing Clin Electrophysiol 1993; 16:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/29\">",
"      Exner DV, Muzyka T, Gillis AM. Proarrhythmia in patients with the Wolff-Parkinson-White syndrome after standard doses of intravenous adenosine. Ann Intern Med 1995; 122:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/30\">",
"      Ross DL, Uther JB. Diagnosis of concealed accessory pathways in supraventricular tachycardia. Pacing Clin Electrophysiol 1984; 7:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/31\">",
"      Pritchett EL, Tonkin AM, Dugan FA, et al. Ventriculo-atrial conduction time during reciprocating tachycardia with intermittent bundle-branch block in Wolff-Parkinson-White syndrome. Br Heart J 1976; 38:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/32\">",
"      Yang Y, Cheng J, Glatter K, et al. Quantitative effects of functional bundle branch block in patients with atrioventricular reentrant tachycardia. Am J Cardiol 2000; 85:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/33\">",
"      Ross DL, Farre J, Bar FW, et al. Spontaneous termination of circus movement tachycardia using an atrioventricular accessory pathway: incidence, site of block and mechanisms. Circulation 1981; 63:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/34\">",
"      Brugada P, Bar FW, Vanagt EJ, Wellens HJ. Observations on mechanisms of circus movement tachycardia in the Wolff-Parkinson-White syndrome. Role of different tachycardia circuits and sites of block in maintenance of tachycardia. Pacing Clin Electrophysiol 1981; 4:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/35\">",
"      Farr&eacute; J, Ross D, Wiener I, et al. Reciprocal tachycardias using accessory pathways with long conduction times. Am J Cardiol 1979; 44:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/36\">",
"      Brugada P, Farr&eacute; J, Green M, et al. Observations in patients with supraventricular tachycardia having a P-R interval shorter than the R-P interval: differentiation between atrial tachycardia and reciprocating atrioventricular tachycardia using an accessory pathway with long conduction times. Am Heart J 1984; 107:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/37\">",
"      Rosenthal M, Oseran DS, Gang E, et al. Verapamil-induced retrograde conduction block in a concealed atrioventricular bypass tract. Am J Cardiol 1985; 55:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/38\">",
"      Bardy GH, Packer DL, German LD, Gallagher JJ. Preexcited reciprocating tachycardia in patients with Wolff-Parkinson-White syndrome: incidence and mechanisms. Circulation 1984; 70:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/39\">",
"      Kuck KH, Brugada P, Wellens HJ. Observations on the antidromic type of circus movement tachycardia in the Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1983; 2:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/40\">",
"      Brugada P, Vanagt EJ, Bar FW, Wellens HJ. Incessant reciprocating atrioventricular tachycardia. Factors playing a role in the mechanism of the arrhythmia. Pacing Clin Electrophysiol 1980; 3:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/41\">",
"      Aguinaga L, Primo J, Anguera I, et al. Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation. Pacing Clin Electrophysiol 1998; 21:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/42\">",
"      Guarnieri T, Sealy WC, Kasell JH, et al. The nonpharmacologic management of the permanent form of junctional reciprocating tachycardia. Circulation 1984; 69:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/43\">",
"      Ticho BS, Saul JP, Hulse JE, et al. Variable location of accessory pathways associated with the permanent form of junctional reciprocating tachycardia and confirmation with radiofrequency ablation. Am J Cardiol 1992; 70:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/44\">",
"      Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/45\">",
"      Deal BJ, Keane JF, Gillette PC, Garson A Jr. Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: management and follow-up. J Am Coll Cardiol 1985; 5:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/46\">",
"      Campbell RW, Smith RA, Gallagher JJ, et al. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol 1977; 40:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/47\">",
"      Wellens HJ, Durrer D. Wolff-Parkinson-White syndrome and atrial fibrillation. Relation between refractory period of accessory pathway and ventricular rate during atrial fibrillation. Am J Cardiol 1974; 34:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/48\">",
"      Timmermans C, Smeets JL, Rodriguez LM, et al. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol 1995; 76:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/49\">",
"      Todd DM, Klein GJ, Krahn AD, et al. Asymptomatic Wolff-Parkinson-White syndrome: is it time to revisit guidelines? J Am Coll Cardiol 2003; 41:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/50\">",
"      Leitch JW, Klein GJ, Yee R, Murdock C. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern. Circulation 1990; 82:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/51\">",
"      Fitzsimmons PJ, McWhirter PD, Peterson DW, Kruyer WB. The natural history of Wolff-Parkinson-White syndrome in 228 military aviators: a long-term follow-up of 22 years. Am Heart J 2001; 142:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/52\">",
"      Klein GJ, Prystowsky EN, Yee R, et al. Asymptomatic Wolff-Parkinson-White. Should we intervene? Circulation 1989; 80:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24025/abstract/53\">",
"      Pappone C, Santinelli V, Rosanio S, et al. Usefulness of invasive electrophysiologic testing to stratify the risk of arrhythmic events in asymptomatic patients with Wolff-Parkinson-White pattern: results from a large prospective long-term follow-up study. J Am Coll Cardiol 2003; 41:239.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 998 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-2.133.93.82-D9A3241E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24025=[""].join("\n");
var outline_f23_29_24025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3190726\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION OF AV ACCESSORY PATHWAY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      In sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      During atrial and ventricular pacing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Detection of multiple accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Use of adjunctive interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ATRIOVENTRICULAR REENTRANT TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PERMANENT JUNCTIONAL RECIPROCATING TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ATRIAL FIBRILLATION AND ATRIAL FLUTTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ASYMPTOMATIC PATIENTS WITH A WPW ECG PATTERN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3190726\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/998\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/998|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/50/22319\" title=\"figure 1\">",
"      Schematic anatomic locations accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/9/25749\" title=\"figure 2\">",
"      Electrograms dual pathways WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/35/15926\" title=\"figure 3\">",
"      Orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/52/35655\" title=\"figure 4\">",
"      Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/49/36628\" title=\"figure 5\">",
"      LBBB and AVRT rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/19/1335\" title=\"figure 6\">",
"      Resetting AVRT extrastimulus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/63/43002\" title=\"figure 7\">",
"      ECG atrial flutter preexcitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/998|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/31/37370\" title=\"waveform 1\">",
"      AF via multiple AV connections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?13/9/13463\" title=\"waveform 2\">",
"      ECG exercise changes on ECG in WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/50/29478\" title=\"waveform 3\">",
"      Orthodromic AVRT tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/16/17670\" title=\"waveform 4\">",
"      WPW orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/2/44072\" title=\"waveform 5\">",
"      ECG Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/52/32585\" title=\"waveform 6\">",
"      EPS tracing AVRT initiation termination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/43/11954\" title=\"waveform 7\">",
"      Electrograms AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?24/45/25296\" title=\"waveform 8\">",
"      ECG WPW left posterior path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?25/13/25814\" title=\"waveform 9\">",
"      Permanent junctional tachy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?41/16/42250\" title=\"waveform 10\">",
"      ECG atrial fibrillation in WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/59/43962\" title=\"waveform 11\">",
"      ECG with atrial fibrillation with preexcitation in WPW syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10853?source=related_link\">",
"      Concealed accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/23/39289?source=related_link\">",
"      Electrophysiologic cardiac mapping: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27305?source=related_link\">",
"      Electrophysiologic cardiac mapping: Use in specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/61/17370?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/9/22681?source=related_link\">",
"      Nonpharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_29_24026="Rapid sequence intubation (RSI) in children";
var content_f23_29_24026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rapid sequence intubation (RSI) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24026/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24026/contributors\">",
"     Dewesh Agrawal, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24026/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24026/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/29/24026/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/29/24026/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/29/24026/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid sequence intubation (RSI) describes a sequential process of preparation, sedation, and paralysis to facilitate safe, emergent tracheal intubation. Pharmacologic sedation and paralysis are induced in rapid succession to quickly and effectively perform laryngoscopy and tracheal intubation. At the same time, careful preparation (including preoxygenation) and the use of specific techniques (such as applying cricoid pressure and avoiding positive pressure ventilation) minimize the risks of hypoxia and aspiration.",
"   </p>",
"   <p>",
"    In the emergency department (ED), RSI is generally the preferred method for emergently intubating patients who have varying levels of consciousness and are presumed to have a full stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success of the procedure depends upon the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sedation and paralysis eliminate protective airway reflexes and spontaneous respiration. Therefore, difficulties with intubation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventilation must be anticipated and contingency plans for a failed intubation developed.",
"     </li>",
"     <li>",
"      The choice of pharmacologic agents for sedation and paralysis is determined based on clinical features that will affect the patient's response to the drug, such as hypotension or preexisting conditions, such as asthma.",
"     </li>",
"     <li>",
"      A simple, systematic approach to preparation and execution of the procedure is necessary to perform it quickly and safely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss evaluation of the patient requiring RSI, as well as choice of pharmacologic agents and the steps involved in performing RSI. Procedures for laryngoscopy and intubation, the difficult pediatric airway, and airway management for adults are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent intubations can be performed with or without sedation and paralysis. The vast majority are performed using rapid sequence intubation (RSI), a specific intubation technique that involves sedation and paralysis, with airway protection. This was demonstrated in a large prospective series, including more than 7000 patients, in which 78 percent of intubations were performed using RSI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RSI is generally preferred because it is more successful and safer than intubation without sedation and paralysis for patients with varying levels of consciousness, active protective airway reflexes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a full stomach. The superiority of RSI, as compared with intubation without sedation and paralysis, has been demonstrated by clinical experience and several small retrospective as well as one large prospective observational series in which success rates for intubation were significantly higher and the incidence of adverse events was significantly lower using RSI in the emergency department (ED) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/3-9\">",
"     3-9",
"    </a>",
"    ]. In addition, randomized, controlled trials describing intubating conditions (such as ease of laryngoscopy, vocal cord movement, and coughing) for patients intubated in the operating room have consistently reported a significantly higher frequency of excellent intubation conditions with deep sedation plus paralysis (80 to 98 percent) versus that observed with deep sedation alone (0 to 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RSI can be safely performed by emergency clinicians trained in advanced airway management, including the use of medications for sedation and paralysis. This has been demonstrated in multiple large series of adult patients and several small pediatric series [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/3,8,9,12,13\">",
"     3,8,9,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sedation and paralysis are unnecessary prior to intubation for some patients, such as those who are in cardiac arrest or already deeply comatose.",
"   </p>",
"   <p>",
"    There are no absolute contraindications to RSI. However, because sedation and paralysis eliminate protective airway reflexes and spontaneous respiration, RSI must be modified for the patient for whom bag-mask ventilation and intubation may be more difficult. An alternative plan that involves assistance from subspecialists (eg, anesthesiologists, otorhinolaryngologists, intensivists) and intubation with sedation, but without paralysis, should be considered for these children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RAPID OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of rapid sequence intubation (RSI) is to quickly and safely intubate patients using sedation and paralysis. In the majority of situations, RSI, from the decision to intubate to successful intubation, is accomplished in less than 10 minutes (",
"    <a class=\"graphic graphic_table graphicRef77060 \" href=\"UTD.htm?12/11/12475\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A rapid overview can be found in an accompanying table (",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"     table 2",
"    </a>",
"    ). It is intended to provide a practical, simplified guide to this process. Each of the steps is discussed in detail in the remainder of the topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREOXYGENATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoxygenation establishes a reservoir of oxygen within the lungs, as well as an oxygen surplus throughout the body. The patient can then tolerate several minutes of apnea without oxygen desaturation, allowing intubation to be safely performed without bag-mask ventilation.",
"   </p>",
"   <p>",
"    Preoxygenation is particularly important for infants and children. Compared with adults, these young patients have a higher oxygen consumption rate, with lower functional residual capacity and alveolar volume [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Consequently, oxygen desaturation occurs much more rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. As an example, arterial oxygen desaturation to 80 percent may occur in a preoxygenated apneic 10 kg infant in less than four minutes, as compared with over eight minutes in a healthy 70 kg adult.",
"   </p>",
"   <p>",
"    For a child who is breathing spontaneously, adequate preoxygenation can generally be achieved using a nonrebreather mask for a minimum of three minutes. From a practical viewpoint, oxygen should be administered at the highest concentration available as soon as RSI is being considered.",
"   </p>",
"   <p>",
"    Many children who require intubation are hypoxic, in respiratory failure, or have insufficient respiratory reserve to achieve adequate preoxygenation with spontaneous respirations. In addition, some may be intermittently apneic or may become apneic with administration of the sedative, before receiving the paralytic agent. In these settings, careful bag-mask ventilation with small tidal volumes (while maintaining cricoid pressure) should be performed for several minutes to achieve adequate preoxygenation. Limited evidence suggests that cricoid pressure during bag-mask ventilation is effective for preventing gastric insufflation, reducing the risk of regurgitation and aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/17\">",
"     17",
"    </a>",
"    ].(See",
"    <a class=\"local\" href=\"#H31\">",
"     'Cricoid pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the preparation phase of rapid sequence intubation (RSI), a treatment plan for intubation based upon the patient's clinical condition must be quickly developed. This is done as the patient is being preoxygenated.",
"   </p>",
"   <p>",
"    A rapid review of key aspects of the child's history, as well as a targeted physical examination helps identify conditions that affect the optimal choices of medications for pretreatment, sedation, paralysis, and postintubation management, as well as a contingency plan in the event of a failed intubation. In addition, equipment for monitoring and airway management should be assembled and its function checked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rapid review of key aspects of the child's history, as well as a targeted physical examination must identify the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preexisting or current conditions that may be adversely affected by medications or airway manipulation (particularly neuromuscular disease, cardiovascular compromise, increased intracranial pressure, or bronchospasm)",
"     </li>",
"     <li>",
"      Clinical features that may make laryngoscopy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tracheal intubation difficult",
"     </li>",
"     <li>",
"      Conditions that may interfere with bag-mask ventilation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following historical information is useful for selecting medications for RSI, as well as anticipating possible difficulties with airway or ventilation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergies to medications",
"     </li>",
"     <li>",
"      History of or concern for neuromuscular disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      renal failure &ndash;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       Succinylcholine",
"      </a>",
"      can cause a clinically significant rise in serum potassium in patients with neuromuscular disease. Some young children with clinical features, such as hypotonia or developmental delay may have a neuromuscular disorder that has not yet been diagnosed. Renal failure per se is not a contraindication to the use of succinylcholine. However, patients with renal failure may have hyperkalemia, which is a contraindication. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Succinylcholine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Family history suggestive of malignant hyperthermia with anesthetics &ndash; Use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      is absolutely contraindicated in patients who have had or have a family history of malignant hyperthermia.",
"     </li>",
"     <li>",
"      Previous intubations or anesthetics &ndash; A difficult intubation in the past or an adverse response to an anesthetic must be considered when developing an intubation treatment plan.",
"     </li>",
"     <li>",
"      History of asthma &ndash; Laryngoscopy may precipitate bronchospasm in children with asthma. In addition, patients with bronchospasm may be difficult to ventilate.",
"     </li>",
"     <li>",
"      Noisy breathing, particularly in sleep, suggests some degree of anatomic upper airway obstruction (such as enlarged tonsils or tongue) that may interfere with laryngoscopy or bag-mask ventilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of the following conditions will influence the choice of medications for pretreatment, induction, and paralysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiovascular compromise, such as unexplained tachycardia, poor peripheral perfusion, or hypotension (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=see_link\">",
"       \"Assessment of perfusion in pediatric resuscitation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased intracranial pressure, including altered mental status or focal neurologic signs",
"     </li>",
"     <li>",
"      Bronchospasm",
"     </li>",
"     <li>",
"      Any condition that could result in hyperkalemia, such as an acute crush injury or renal failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Problems with effective bag-mask ventilation or difficult laryngoscopy and intubation can occur in children with certain physical features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link\">",
"     \"The difficult pediatric airway\"",
"    </a>",
"    .) These features include the following (",
"    <a class=\"graphic graphic_table graphicRef71326 \" href=\"UTD.htm?4/52/4939\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hoarseness, stridor, drooling, or an upright position of comfort indicates the presence of upper airway obstruction.",
"     </li>",
"     <li>",
"      A child with a prominent occiput or misshapen head may be difficult to position optimally for bag-mask ventilation or laryngoscopy.",
"     </li>",
"     <li>",
"      Facial anomalies, including burns or other trauma, can make it difficult to obtain an adequate seal for bag-mask ventilation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small mouth, abnormal palate, large tongue, or a small mandible all suggest that laryngoscopy will be difficult because of decreased space within the oral cavity and mandible.",
"     </li>",
"     <li>",
"      Short neck or poor mobility of the neck (congenital anomaly, cervical spine immobilization) may interfere with positioning of the head and neck.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intubation treatment plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to choosing medications, an intubation treatment plan should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications for pretreatment, sedation, paralysis, and postintubation management should be drawn up in weight or length-based doses, doses verified, and syringes carefully labeled.",
"     </li>",
"     <li>",
"      A contingency plan for failed intubation must be delineated when a difficult airway is anticipated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link&amp;anchor=H23#H23\">",
"       \"The difficult pediatric airway\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Roles should be clearly assigned to each healthcare provider, including an assistant to the intubator and someone to apply cricoid pressure. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Cricoid pressure'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Equipment and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The equipment and monitoring that are necessary for children receiving RSI are the same as for any patient requiring advanced airway management (",
"    <a class=\"graphic graphic_table graphicRef71484 \" href=\"UTD.htm?10/35/10812\">",
"     table 4",
"    </a>",
"    ). No medications for induction or paralysis should be administered until the equipment, including suction, is assembled and tested for function. In addition, the child must be accurately monitored for oxygen saturation, heart rate, and blood pressure. Once intubation is performed, monitoring should also include end-tidal carbon dioxide (CO2) detection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PRETREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manipulation of the airway with a laryngoscope and endotracheal tube results in predictable physiologic responses (increase or decrease in heart rate, increase in intracranial pressure, rise in systemic blood pressure, and increase in airway resistance). Pretreatment with agents that attenuate these responses may be beneficial for conditions, such as brain injury or reactive airways.",
"   </p>",
"   <p>",
"    Rapid sequence intubation (RSI) becomes more complex and takes longer with the addition of each medication. Consequently, the decision of whether or not to use additional agents must include consideration of the potential benefit to the patient, as well as possible adverse consequences of a prolonged procedure or unanticipated drug responses.",
"   </p>",
"   <p>",
"    Medications that are usually considered for pretreatment include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    , opiates, and muscle relaxants for defasciculation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Atropine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children, particularly young infants, may have a pronounced vagal response (eg, bradycardia with poor perfusion) to laryngoscopy. In addition, bradycardia and asystole have been reported in children receiving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/18\">",
"     18",
"    </a>",
"    ]. We therefore suggest the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    with RSI for all children younger than one year, for those less than five years of age receiving succinylcholine, and for children older than five years requiring a second dose of succinylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/1,2,15\">",
"     1,2,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    for pretreatment in RSI is 0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum 0.5 mg) IV. Atropine in too small a dose may cause paradoxical bradycardia. Therefore, the minimum dose that should be administered is 0.1 mg.",
"   </p>",
"   <p>",
"    Evidence supporting the efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    to prevent bradycardia is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two small trials in neonates have demonstrated that bradycardia occurred but was significantly less in infants who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      prior to laryngoscopy and endotracheal intubation than those who didn't (mean heart rate decrease 29 to 36 beats per minute in pretreated neonates versus 52 to 68 beats per minute in controls) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An observational study of 143 children who were intubated in a pediatric emergency department (ED) found six episodes of bradycardia with laryngoscopy. Three of 68 patients pretreated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      experienced bradycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/22\">",
"       22",
"      </a>",
"      ]. However, two of these patients were hypoxemic prior to intubation and the remaining patient had an intracranial injury. In addition,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      was used as the paralytic in only 11 percent of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     Atropine",
"    </a>",
"    is also an anti-sialogogue. However, this effect is not immediate, limiting its usefulness for this indication in RSI.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     Atropine",
"    </a>",
"    may dampen the ability to assess the patient's cardiovascular and neurologic status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      on heart rate may persist for several hours and prevent the bradycardic response to hypoxemia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       Atropine",
"      </a>",
"      dilates the pupils, thus interfering with pupillary response to light as a means to evaluate a change in neurologic status once the patient is paralyzed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Lidocaine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    is optional for RSI in children who may have increased intracranial pressure (ICP) to lessen any additional increase in ICP associated with laryngoscopy and intubation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. This benefit may be related to suppression of cough and gag reflexes as well as to effects on cerebral perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence regarding the effectiveness of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    for this indication comes from studies in adults and has been inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/25\">",
"     25",
"    </a>",
"    ]. Whether or not lidocaine improves upon neuroprotection provided by",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    , is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Sedative and induction agents'",
"    </a>",
"    below.) There have been no reports of adverse effects from lidocaine when used to blunt ICP response to airway manipulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     Lidocaine",
"    </a>",
"    has also been used in adult populations to decrease bronchospasm caused by airway manipulation. Evidence supporting this practice is conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/28\">",
"     28",
"    </a>",
"    ]. There are no data to support or refute this practice in children.",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    for pretreatment in RSI is 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment with opioids is not generally recommended for children [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/15,26\">",
"     15,26",
"    </a>",
"    ]. Children receiving reliable sedatives, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    rapidly become unconscious. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Sedative and induction agents'",
"    </a>",
"    below.) In addition, adverse reactions, particularly hypotension or respiratory depression, can occur when opioids are used in conjunction with other sedating medications. Analgesia with opioids should be provided as part of postintubation care. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Postintubation management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Opioids (usually",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) are used for pretreatment in adults to attenuate the reflex sympathetic response that occurs with laryngoscopy. This transient increase in heart rate and blood pressure can have an adverse effect for conditions rarely observed in children, such as aortic dissection or aortic aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Defasciculating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defasciculating agents (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"     rocuronium",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/49/43797?source=see_link\">",
"     vecuronium",
"    </a>",
"    at one-tenth of the paralyzing dose) are not routinely recommended for children receiving",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Succinylcholine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SEDATION AND PARALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two essential medications used in rapid sequence intubation (RSI) are a sedative and a paralytic. The sedative agent must always be administered first, followed rapidly by a paralytic, once the child becomes unconscious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sedative and induction agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal sedative for RSI rapidly induces unconsciousness and has a short duration of action, with minimal side effects (",
"    <a class=\"graphic graphic_table graphicRef64272 \" href=\"UTD.htm?35/29/36316\">",
"     table 5",
"    </a>",
"    ). The presence of the following factors must be considered when choosing a sedative:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiovascular instability",
"     </li>",
"     <li>",
"      Neurologic abnormalities (seizure, increased intracranial pressure)",
"     </li>",
"     <li>",
"      Bronchospasm or a history of asthma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Etomidate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     Etomidate",
"    </a>",
"    is an ultrashort-acting, imidazole derivative that produces reliable sedation and induction for RSI without causing significant hemodynamic compromise. It is the sedative administered most frequently in adult patients for RSI in the emergency department (ED), with increasing use for children as well [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/3,9,29-32\">",
"     3,9,29-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H5#H5\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Etomidate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    used in RSI is 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV.",
"   </p>",
"   <p>",
"    The following evidence supports the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    for RSI for children in the ED:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective series describing children who received",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      for RSI in a pediatric ED, good intubating conditions (as judged by good vocal cord position, no patient reaction to intubation, and adequate jaw relaxation) were achieved in 68 of 69 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/33\">",
"       33",
"      </a>",
"      ]. Transient hypotension developed after the administration of etomidate in seven patients (five did not require intervention, one had hemorrhagic shock, and one had septic shock).",
"     </li>",
"     <li>",
"      A systematic review that included one retrospective pediatric series concluded that, although evidence is limited,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      is an effective sedative for RSI in the ED, even in hypovolemic patients or those with limited cardiac reserve [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/30,34\">",
"       30,34",
"      </a>",
"      ]. A retrospective pediatric series that was not included in the systematic review supports these conclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     Etomidate",
"    </a>",
"    reliably decreases intracranial pressure (ICP) and cerebral metabolic rate, suggesting that it has a neuroprotective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. Etomidate also has a protective effect similar to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    for generalized seizure activity. However, it may lower seizure threshold in patients with focal seizure disorders and should be used with caution in this situation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myoclonus has been reported as an adverse effect associated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    . It does not generally interfere with intubation when paralytics are also used [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     Etomidate",
"    </a>",
"    inhibits 11-B-hydroxylase, an enzyme important in adrenal steroid production. Transient adrenocortical suppression following a single dose of etomidate has been demonstrated in adults in numerous small randomized trials. This observation may not be clinically significant in patients with normal adrenocortical function. Limited low quality evidence in children suggests that etomidate may adversely affect outcome in patients who already have some degree of adrenocortical suppression, such as those with severe sepsis. The 2007 update to the Clinical Guidelines for Hemodynamic Support of Neonates and Children with Septic Shock from the American College of Critical Care Medicine states that etomidate is no longer recommended to sedate children with septic shock. The 2010 advanced life support recommendations provided by the American Heart Association and the International Liaison Committee on Resuscitation also suggest that etomidate",
"    <strong>",
"     not",
"    </strong>",
"    be used routinely in children with septic shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19450192#H19450192\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Airway and breathing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest the following approach in children with septic shock:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      , if available and not contraindicated, is preferable for sedating a child in septic shock prior to rapid sequence intubation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H10#H10\">",
"       \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Ketamine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      should not be used routinely in children with septic shock. If etomidate is used, we suggest that, if the patient has septic shock refractory to fluids and vasopressors, a single dose of a corticosteroid, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      be given. Hydrocortisone interferes with the short ACTH stimulation test, while dexamethasone does not, so intensivists may prefer the latter if the diagnosis of adrenal insufficiency is unclear. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19450192#H19450192\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Airway and breathing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Emergency clinicians should inform the physicians assuming care for the patient in the intensive care unit when",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      has been used for induction.",
"     </li>",
"     <li>",
"      Testing to determine the presence of adrenal insufficiency should be performed if possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19450192#H19450192\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Airway and breathing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      should not be used as an infusion or in repeated bolus doses for maintenance of sedation after intubation.",
"     </li>",
"     <li>",
"      The use of corticosteroids for the treatment of septic shock in general is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link\">",
"       \"Corticosteroid therapy in septic shock\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    for RSI in adults with septic shock is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H7#H7\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Adrenocortical suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Thiopental",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"     Thiopental",
"    </a>",
"    is a short-acting barbiturate with a rapid onset of action that has been used extensively for sedation and induction in RSI. It may provide better intubating conditions than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    , as was demonstrated in one large, prospective, observational series of adults and children where successful intubation on the first attempt was more likely with thiopental than with etomidate [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/29\">",
"     29",
"    </a>",
"    ]. However, thiopental causes vasodilatation and myocardial depression, resulting in a decrease in systolic blood pressure. Thus, it should not be used in patients with cardiovascular instability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H9#H9\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Barbiturates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As long as cerebral perfusion pressure is maintained,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    provides neuroprotection through reduction in cerebral oxygen consumption and blood flow. It also has anticonvulsant properties, making it a preferred sedative for patients with neurologic injury who are hemodynamically stable.",
"   </p>",
"   <p>",
"    Finally,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    causes histamine release that may contribute to a decrease in systolic blood pressure and be clinically significant in patients with reactive airways.",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    used in RSI is 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV. Production of thiopental was discontinued by the sole United States manufacturer in 2011 extremely limiting US availability [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Ketamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     Ketamine",
"    </a>",
"    is a dissociative anesthetic that is derived from phencyclidine. It produces rapid sedation, amnesia, and analgesia while preserving protective airway reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/1,41,42\">",
"     1,41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H10#H10\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Ketamine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     Ketamine",
"    </a>",
"    causes catecholamine release, thus augmenting heart rate and blood pressure in patients who are not catecholamine depleted. It is therefore useful in patients who are hemodynamically unstable.",
"   </p>",
"   <p>",
"    Catecholamine release associated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    also results in bronchodilatation. It is therefore useful for RSI in patients with bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/43-46\">",
"     43-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence suggesting that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    elevates intracranial pressure and is therefore harmful for patients with head injury is weak. On the other hand, ketamine has anticonvulsant properties and may benefit patients with neurologic injury by increasing cerebral perfusion, particularly those who are hypotensive. The use of ketamine for patients with head injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H12#H12\">",
"     \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Elevated intracranial pressure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial studies in children indicated",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    was a potent sialogogue and recommended premedication with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, more recent evidence suggests that excessive salivation is uncommon in doses typically used for rapid sequence intubation (RSI). As an example, in 947 pediatric sedations performed without atropine, significant salivation was reported in approximately 1 percent of patients and was felt to cause airway complications in only one instance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/49\">",
"     49",
"    </a>",
"    ]. Thus, the use of anticholinergic premedication for ketamine sedation during RSI is",
"    <strong>",
"     not",
"    </strong>",
"    routinely necessary.",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    used in RSI is 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Propofol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     Propofol",
"    </a>",
"    is a highly lipid soluble, nonbarbiturate sedative-hypnotic that produces general anesthesia. The onset of effect is extremely rapid, with short duration of action.",
"   </p>",
"   <p>",
"    However, the following characteristics limit its usefulness for RSI for patients who are hemodynamically unstable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasodilatation and myocardial depression are even more pronounced with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      than with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The neuroprotective effect of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"      can be offset by a decrease in cerebral perfusion pressure as a result of decreased arterial pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Formulations of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    contain egg lecithin, egg yolk phospholipids, and soybean oil. Consequently, children with allergies to egg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    soybeans should not receive propofol, whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"     propofol",
"    </a>",
"    used in RSI is 1.5 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Midazolam",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     Midazolam",
"    </a>",
"    is a rapid-acting benzodiazepine with potent amnestic and anticonvulsant properties, as well as a short duration of action [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/1,41,51\">",
"     1,41,51",
"    </a>",
"    ]. It is used commonly for sedation and induction in RSI in children and adults, accounting for nearly 18 percent of sedatives used in one large prospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/9,29\">",
"     9,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Time to clinical effect is longer for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    than for any of the other sedative agents. Midazolam is frequently underdosed when used for RSI, which may contribute to this observation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/52\">",
"     52",
"    </a>",
"    ]. However, several reports have noted that it inconsistently induces unconsciousness, even at appropriate doses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/24,53\">",
"     24,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     Midazolam",
"    </a>",
"    also causes respiratory depression. As a result, patients may develop apnea before they have received a paralytic agent, decreasing the effectiveness of preoxygenation prior to intubation.",
"   </p>",
"   <p>",
"    Finally,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    has a myocardial depressant effect and produces a dose-related reduction in systemic vascular resistance. It should not be used in hemodynamically compromised patients.",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"     midazolam",
"    </a>",
"    used for RSI is 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV. This is significantly higher than the dose typically used for procedural sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;No ideal sedative exists for every RSI situation. We suggest the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"     thiopental",
"    </a>",
"    for the uncomplicated patient undergoing RSI.",
"   </p>",
"   <p>",
"    We suggest the following agents based upon the presence of specific clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypotension:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      (in patients who are non-catecholamine depleted or in septic shock)",
"     </li>",
"     <li>",
"      Increased ICP:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/48/12039?source=see_link\">",
"       propofol",
"      </a>",
"     </li>",
"     <li>",
"      Hypotensive with head injury:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"     </li>",
"     <li>",
"      Status asthmaticus:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"     </li>",
"     <li>",
"      Status epilepticus:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      ;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      (in patients with hypotension)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paralytic agents provide complete muscle relaxation, which facilitates rapid tracheal intubation. They do not provide sedation, analgesia, or amnesia. As a result, a sedative agent must also be used both for RSI and when paralysis is maintained after intubation. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Sedative and induction agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Succinylcholine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    has been used extensively for RSI. It is a depolarizing agent that mimics the effect of acetylcholine at the nicotinic cholinergic receptor, causing continuous depolarization of the muscle membrane. This inhibits repolarization, resulting in paralysis.",
"   </p>",
"   <p>",
"    Many clinicians consider",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    the ideal paralytic for RSI. This is principally because of its rapid onset of effect (30 to 60 seconds, IV) and short duration of action (four to six minutes, IV). Evidence regarding the relative efficacy of succinylcholine versus other paralytic agents is presented in the next section. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Rocuronium'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are several serious adverse effects that must be considered in order to use",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    safely. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bradycardia following the administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      occurs more commonly in children. The risks of bradycardia and, sometimes, asystole are more significant when repeated doses of succinylcholine are administered [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/1,54\">",
"       1,54",
"      </a>",
"      ]. To avoid these complications, most experts recommend pretreating with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      for children less than five years of age and for all patients when a second dose is required. Repeated doses of succinylcholine should be avoided whenever possible. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Atropine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In certain clinical settings, life-threatening hyperkalemia can occur following the administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      :",
"     </li>",
"     <li>",
"      In conditions that result in the upregulation of skeletal muscle acetylcholine receptors (such as motor neuron lesions, muscle injury, muscle disuse, or muscle atrophy), exaggerated potassium efflux from muscle occurs after depolarization, resulting in a life-threatening increase in serum potassium [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/55\">",
"       55",
"      </a>",
"      ]. An increase in the number of receptors usually occurs within two to three days following an injury.",
"     </li>",
"     <li>",
"      In patients with myopathies, such as Duchenne or Becker's dystrophy,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      interacts with the unstable muscle membrane, causing rhabdomyolysis and a rapid increase in plasma potassium. There have been multiple case reports of hyperkalemia and cardiac arrest as a result of this mechanism in patients with undiagnosed myopathies who have received succinylcholine [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malignant hyperthermia can be triggered by",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link&amp;anchor=H2139843#H2139843\">",
"       \"Severe hyperthermia (heat stroke) in adults\", section on 'Malignant hyperthermia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated ICP with the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      has been reported in animal studies and in humans with brain tumors. Although a systematic review found no definitive evidence that succinylcholine causes a rise in ICP in humans with brain injury, the available studies are small and of poor quality [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated intraocular pressure has been described with the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      . This has raised concerns regarding its use for patients with penetrating eye injuries [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/59\">",
"       59",
"      </a>",
"      ]. However, no cases of vitreous extrusion have been reported with the use of succinylcholine for patients with an open globe [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result of these adverse effects, the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    is",
"    <strong>",
"     absolutely",
"    </strong>",
"    contraindicated under the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/24,56,61\">",
"     24,56,61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic myopathy or denervating neuromuscular disease",
"     </li>",
"     <li>",
"      48 to 72 hours after burns, a crush injury, or an acute denervating event",
"     </li>",
"     <li>",
"      History of malignant hyperthermia",
"     </li>",
"     <li>",
"      Preexisting hyperkalemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications to the use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased intracranial and increased intraocular pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Known pseudocholinesterase deficiency (risk for prolonged duration of action) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    for infants and young children is 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV, which is higher than that recommended in adults. This is because succinylcholine is rapidly distributed in extracellular water, and young children have a larger relative volume of extracellular fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/15,61\">",
"     15,61",
"    </a>",
"    ]. For older children, 1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Rocuronium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"     Rocuronium",
"    </a>",
"    is a nondepolarizing paralytic agent that induces muscle paralysis by competitive antagonism at the nicotinic cholinergic receptor. It has a rapid onset of effect (30 to 60 seconds, IV), but a duration of action that is considerably longer than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    (30 to 40 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"     Rocuronium",
"    </a>",
"    has none of the adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , making it a safe and efficacious alternative. As a result, some experts prefer the disadvantage of a longer duration of paralysis with rocuronium to the small risk of using succinylcholine for a child with an undiagnosed contraindication, such as a congenital myopathy or malignant hyperthermia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    is more likely to provide excellent intubating conditions compared with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"     rocuronium",
"    </a>",
"    . This was demonstrated in a systematic review in which intubating conditions with succinylcholine were compared with those with rocuronium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/62\">",
"     62",
"    </a>",
"    ]. Among 26 randomized trials (three of which were in children) using a validated score to assess intubating conditions, excellent conditions were significantly less likely with rocuronium versus succinylcholine (relative risk 0.87, 95% CI 0.81-0.94). However, there was no difference between succinylcholine and rocuronium for providing clinically acceptable intubating conditions.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"     rocuronium",
"    </a>",
"    may be influenced by the dose. Randomized trials in children and adults have demonstrated that intubating conditions are significantly better with 0.9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose for children and 1 to 1.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose for adults, as compared with 0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. In addition, rocuronium at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    was equivalent to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    for producing clinically acceptable intubating conditions in these reports. However, the duration of action of rocuronium is longer at the higher dose [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/62,64\">",
"     62,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"     rocuronium",
"    </a>",
"    , at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    as the paralytic agent for RSI when",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    may be contraindicated. Superior intubating conditions are a more important consideration than prolonged duration of action under these circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Vecuronium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/49/43797?source=see_link\">",
"     Vecuronium",
"    </a>",
"    is the nondepolarizing agent from which",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"     rocuronium",
"    </a>",
"    was developed. Like rocuronium, it has a favorable safety profile. However, to achieve as rapid an onset of action as rocuronium, higher doses of vecuronium (eg, 0.15-0.2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    must be used, which also prolongs paralysis in an unpredictable fashion. In two trials that compared vecuronium with rocuronium for rapid sequence intubation (RSI), intubating conditions were less optimal in patients who received vecuronium compared to those who received rocuronium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. For these reasons, its usefulness for RSI is limited. Vecuronium should be used with extreme caution in patients for whom endotracheal intubation is predicted to be difficult.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Pancuronium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/0/34821?source=see_link\">",
"     Pancuronium",
"    </a>",
"    is a longer acting nondepolarizing neuromuscular blocking agent that is predominantly used to maintain paralysis after RSI (duration of effect 120 to 150 minutes). Its slower onset of action limits its use in RSI. Pancuronium also has a pronounced vagolytic effect that increases heart rate, blood pressure, and cardiac output.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PROTECTION AND POSITIONING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protection during rapid sequence intubation (RSI) refers to protecting the airway by preventing regurgitation of gastric contents and aspiration. This is accomplished with cricoid pressure and by avoiding bag-mask ventilation. In addition, cervical spine protection must be maintained when injury is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Cricoid pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cricoid pressure is often used in pediatric RSI to reduce gastric insufflation during bag-mask ventilation and to prevent passive regurgitation of gastric contents [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/68\">",
"     68",
"    </a>",
"    ]. In this technique, often referred to as the Sellick maneuver, the thumb and fore or middle finger are used to apply pressure over the anterior neck at the cricoid cartilage to compress the esophagus between the cricoid cartilage and the anterior surface of the C6 vertebral body (",
"    <a class=\"graphic graphic_figure graphicRef71800 \" href=\"UTD.htm?21/53/22354\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When used, cricoid pressure should be applied after the sedative is administered, once the child becomes unconscious. It should be maintained until tracheal tube position is verified.",
"   </p>",
"   <p>",
"    Cricoid pressure has been considered essential for the protection of the airway during RSI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/68\">",
"     68",
"    </a>",
"    ]. However, evidence supporting the effectiveness of the technique for preventing regurgitation is limited and conflicting. A systematic review of cricoid pressure noted the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/29/24026/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence supporting the technique includes cadaver studies and small case series.",
"     </li>",
"     <li>",
"      Case series and retrospective reviews describe failure of cricoid pressure to prevent aspiration.",
"     </li>",
"     <li>",
"      Cricoid pressure may be used inconsistently and applied improperly in emergency settings.",
"     </li>",
"     <li>",
"      Even healthcare workers who perform the procedure frequently may often do so incorrectly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risks associated with the Sellick maneuver include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Difficulty viewing the larynx during intubation",
"     </li>",
"     <li>",
"      Airway obstruction when ventilation is required",
"     </li>",
"     <li>",
"      Movement of the cervical spine in patients with unstable fractures",
"     </li>",
"     <li>",
"      Esophageal injury in patients who are actively vomiting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite conflicting evidence regarding the effectiveness of cricoid pressure for preventing regurgitation, clinical experience suggests that in most situations, it is not harmful and may be beneficial. We therefore suggest that cricoid pressure be used initially with RSI. However, cricoid pressure should be removed if airway obstruction occurs when ventilation is required or if there is difficulty viewing the larynx.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Bag-mask ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Every effort must be made to avoid bag-mask ventilation (BMV) during RSI, because of the increased risk of vomiting and aspiration that can occur with gastric distention following BMV. However, in patients who cannot be adequately preoxygenated, BMV with small tidal volumes and cricoid pressure is preferable to intubating a hypoxic patient. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Preoxygenation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper positioning aligns the pharyngeal, tracheal, and oral axes (",
"    <a class=\"graphic graphic_picture graphicRef69636 \" href=\"UTD.htm?1/55/1908\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For children with suspected injury of the cervical spine, positioning must be accomplished without moving the neck. In-line manual stabilization must be maintained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H16#H16\">",
"     \"Emergent endotracheal intubation in children\", section on 'Positioning'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H17#H17\">",
"     \"Emergent endotracheal intubation in children\", section on 'Cervical spine immobilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     PLACEMENT, WITH CONFIRMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onset of paralysis generally occurs within 30 to 60 seconds following the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"     succinylcholine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"     rocuronium",
"    </a>",
"    . Once the child has become apneic, muscle relaxation can be confirmed by testing the jaw for flaccidity. Relaxation is adequate when the jaw can be easily opened. Once adequate muscle relaxation is confirmed, laryngoscopy can be performed with careful attention to proper technique. Oropharyngeal injury can be minimized, while effectively exposing the glottic aperture. After the tracheal tube has been placed and stylet removed, tube placement must be confirmed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H20#H20\">",
"     \"Emergent endotracheal intubation in children\", section on 'Laryngoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H24#H24\">",
"     \"Emergent endotracheal intubation in children\", section on 'Confirming tube position'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     POSTINTUBATION MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following placement and confirmation, the tracheal tube should be appropriately secured and a chest radiograph obtained to document proper placement and evaluate pulmonary status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link&amp;anchor=H25#H25\">",
"     \"Emergent endotracheal intubation in children\", section on 'Post-intubation care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ongoing sedation and analgesia, generally with paralysis, is essential for as long as the patient requires advanced airway support. Hemodynamic considerations generally dictate which pharmacologic agents should be used. A benzodiazepine (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    ) is often used in combination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/0/34821?source=see_link\">",
"     pancuronium",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/49/43797?source=see_link\">",
"     vecuronium",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Sedative and induction agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For children with a stable blood pressure, opioid analgesia (such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"     fentanyl",
"    </a>",
"    ) should be added.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid sequence intubation (RSI) provides optimal conditions for emergent intubation. We recommend that clinicians who are trained in tracheal intubation use RSI for most children who require emergent intubation who are not in cardiac arrest or already deeply comatose (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). A simple, systematic approach to preparation and execution of the procedure is necessary in order to perform RSI quickly and safely (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RSI must be modified for the patient for whom bag-mask ventilation and intubation may be more difficult. An alternative plan that involves assistance from subspecialists (anesthesiologists, otorhinolaryngologists, intensivists) and intubation with sedation, but without paralysis, should be considered for these patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link&amp;anchor=H12#H12\">",
"       \"The difficult pediatric airway\", section on 'Identification of the difficult pediatric airway'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=see_link&amp;anchor=H23#H23\">",
"       \"The difficult pediatric airway\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The sequential steps involved in RSI are summarized below. The factors underlying the decision to intubate, as well as procedures for laryngoscopy and intubation are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Preoxygenation",
"      </strong>",
"      &ndash; Preoxygenation is a critical step in RSI, particularly for children. Oxygen should be administered at the highest concentration available as soon as RSI is being considered. Children who have insufficient respiratory reserve or who are experiencing apnea may require careful bag-mask ventilation with small tidal volumes (while maintaining cricoid pressure) to achieve adequate preoxygenation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Preoxygenation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Preparation",
"      </strong>",
"      &ndash; In the preparation phase of RSI, a rapid review of key aspects of the child's history, as well as a targeted physical examination, helps identify conditions that affect the optimal choices of medications. In addition, equipment for monitoring and airway management should be assembled and its function checked. This is done as the patient is being preoxygenated (",
"      <a class=\"graphic graphic_table graphicRef71326 \" href=\"UTD.htm?4/52/4939\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef71484 \" href=\"UTD.htm?10/35/10812\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Pretreatment",
"      </strong>",
"      &ndash; Medications used for pretreatment attenuate physiologic responses to laryngoscopy and tracheal intubation. The principal adverse responses in children are bradycardia and increased intracranial pressure (ICP). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pretreatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      to prevent bradycardia for all",
"      <strong>",
"       children",
"      </strong>",
"      one year of age or younger and for children less than five years of age who are receiving",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      for paralysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Atropine should also be given to children older than five years who are receiving a second dose of succinylcholine. However, repeated doses of succinylcholine should be avoided whenever possible. The dose of atropine for pretreatment in RSI is 0.02",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 0.5 mg) IV. A minimum dose of 0.1 mg should be used to avoid paradoxical bradycardia. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Atropine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"       lidocaine",
"      </a>",
"      is optional for RSI in children with possible increased ICP. Evidence regarding the effectiveness of lidocaine for this indication comes from studies in adults and has been inconsistent. Whether or not lidocaine improves upon neuroprotection provided by",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      , is unknown. The dose of lidocaine for pretreatment in RSI is 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Lidocaine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Sedation",
"      </strong>",
"      &ndash; Two essential medications used in RSI are a sedative and a paralytic. The sedative agent must always be administered first, followed rapidly by a paralytic, once the child becomes unconscious. Important issues that determine the optimal agents for sedation include hemodynamic instability, need for neuroprotection, and history of bronchospasm (",
"      <a class=\"graphic graphic_table graphicRef64272 \" href=\"UTD.htm?35/29/36316\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Sedative and induction agents'",
"      </a>",
"      above.) The following are our recommendations for the preferred sedative agent for any given patient based on the presence or absence of these clinical features:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For hemodynamically",
"      <strong>",
"       stable",
"      </strong>",
"      children, we suggest using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      as the sedative agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recognize that thiopental may not be commercially available, and others may choose",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      because of concern for unanticipated hypotension with thiopental in patients who initially appear stable. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Thiopental'",
"      </a>",
"      above.) The dose of etomidate used in RSI is 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV. The dose of thiopental used in RSI is 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV.",
"     </li>",
"     <li>",
"      For children with suspected increased ICP who are hemodynamically stable, we suggest using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      as the sedative agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For children with suspected increased ICP who are hemodynamically unstable, we suggest using etomidate (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For children with bronchospasm, septic shock, or a history of asthma, we suggest administering",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      for sedation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This can be given to both hemodynamically stable and unstable patients. The dose of ketamine used in RSI is 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Ketamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hemodynamically",
"      <strong>",
"       unstable",
"      </strong>",
"      children in septic shock, we suggest NOT using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      as a sedative agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      , if available and not contraindicated, is preferable. For hemodynamically unstable children with septic shock who do receive etomidate for induction for RSI, we suggest that they also receive a single dose of a corticosteroid, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Etomidate should not be used as an infusion or in repeated bolus doses for maintenance of sedation after intubation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Etomidate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children in status epilepticus, we suggest using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/13/11478?source=see_link\">",
"       thiopental",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/46/746?source=see_link\">",
"       midazolam",
"      </a>",
"      for sedation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For the patient in status epilepticus who is hemodynamically unstable, we suggest using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The dose of midazolam used for RSI is 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Paralysis",
"      </strong>",
"      &ndash; Paralytic agents provide complete muscle relaxation, which facilitates laryngoscopy and rapid tracheal intubation. They do not provide sedation, analgesia, or amnesia. The following are our recommendations concerning the optimal paralytic agent (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Paralysis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Unless contraindicated, we suggest using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      for paralysis for children (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The dose of succinylcholine for infants and young children is 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV. Older children should receive 1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg.",
"      </span>",
"      However, a significant number of absolute and relative contraindications exist. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Succinylcholine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/58/39845?source=see_link\">",
"       succinylcholine",
"      </a>",
"      cannot be used, we recommend using",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/37/12886?source=see_link\">",
"       rocuronium",
"      </a>",
"      as a paralytic agent (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest using rocuronium at a dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Intubating conditions with this dose of rocuronium are superior to those using rocuronium at a lower dose. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Rocuronium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Protection and positioning",
"      </strong>",
"      &ndash; Cricoid pressure and avoiding bag-mask ventilation may protect the airway by preventing regurgitation of gastric contents and aspiration. We suggest that cricoid pressure be used initially with RSI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, cricoid pressure should be removed if there is difficulty viewing the larynx or airway obstruction occurs when ventilation is required. Cricoid pressure should be applied after administration of the sedative, as soon as the child becomes unconscious. It should not be released until tracheal tube placement is confirmed. Bag-mask ventilation (using small tidal volumes and cricoid pressure) should be performed only when required to maintain oxygenation. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Protection and positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Placement, with confirmation",
"      </strong>",
"      &ndash; Laryngoscopy and tracheal intubation may be performed once adequate muscle relaxation is confirmed. Tracheal placement should be confirmed by primary methods (such as auscultation for breath sounds over lung fields and stomach, the appearance of mist inside the tracheal tube, and symmetric chest rise with positive pressure ventilation) as well as confirmation with detection of end-tidal carbon dioxide. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Placement, with confirmation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=see_link\">",
"       \"Carbon dioxide monitoring (capnography)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Postintubation management",
"      </strong>",
"      &ndash; Following placement and confirmation, the tracheal tube should be appropriately secured. A chest radiograph should also be obtained to document proper placement and evaluate pulmonary status. Ongoing sedation, analgesia, and paralysis are required. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Postintubation management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/1\">",
"      Gerardi MJ, Sacchetti AD, Cantor RM, et al. Rapid-sequence intubation of the pediatric patient. Pediatric Emergency Medicine Committee of the American College of Emergency Physicians. Ann Emerg Med 1996; 28:55.",
"     </a>",
"    </li>",
"    <li>",
"     American Heart Association. Pharmacology. In: Pediatric Advanced Life Support Manual, American Heart Association, 2006. p.228.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/3\">",
"      Sagarin MJ, Barton ED, Chng YM, et al. Airway management by US and Canadian emergency medicine residents: a multicenter analysis of more than 6,000 endotracheal intubation attempts. Ann Emerg Med 2005; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/4\">",
"      Bair AE, Filbin MR, Kulkarni RG, Walls RM. The failed intubation attempt in the emergency department: analysis of prevalence, rescue techniques, and personnel. J Emerg Med 2002; 23:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/5\">",
"      Li J, Murphy-Lavoie H, Bugas C, et al. Complications of emergency intubation with and without paralysis. Am J Emerg Med 1999; 17:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/6\">",
"      Brownstein D, Shugerman R, Cummings P, et al. Prehospital endotracheal intubation of children by paramedics. Ann Emerg Med 1996; 28:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/7\">",
"      Syverud SA, Borron SW, Storer DL, et al. Prehospital use of neuromuscular blocking agents in a helicopter ambulance program. Ann Emerg Med 1988; 17:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/8\">",
"      Gnauck K, Lungo JB, Scalzo A, et al. Emergency intubation of the pediatric medical patient: use of anesthetic agents in the emergency department. Ann Emerg Med 1994; 23:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/9\">",
"      Sagarin MJ, Chiang V, Sakles JC, et al. Rapid sequence intubation for pediatric emergency airway management. Pediatr Emerg Care 2002; 18:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/10\">",
"      Naguib M, Samarkandi A, Riad W, Alharby SW. Optimal dose of succinylcholine revisited. Anesthesiology 2003; 99:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/11\">",
"      Naguib M, Samarkandi AH, El-Din ME, et al. The dose of succinylcholine required for excellent endotracheal intubating conditions. Anesth Analg 2006; 102:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/12\">",
"      Sakles JC, Laurin EG, Rantapaa AA, Panacek EA. Airway management in the emergency department: a one-year study of 610 tracheal intubations. Ann Emerg Med 1998; 31:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/13\">",
"      Marvez-Valls E, Houry D, Ernst AA, et al. Protocol for rapid sequence intubation in pediatric patients -- a four-year study. Med Sci Monit 2002; 8:CR229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/14\">",
"      Benumof JL, Dagg R, Benumof R. Critical hemoglobin desaturation will occur before return to an unparalyzed state following 1 mg/kg intravenous succinylcholine. Anesthesiology 1997; 87:979.",
"     </a>",
"    </li>",
"    <li>",
"     Luten, RC, Kissoon, N. Approach to the pediatric airway. In: Manual of emergency airway management, Walls, RM, Murphy, MF, Luten, RC, et al (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.212.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/16\">",
"      Patel R, Lenczyk M, Hannallah RS, McGill WA. Age and the onset of desaturation in apnoeic children. Can J Anaesth 1994; 41:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/17\">",
"      Moynihan RJ, Brock-Utne JG, Archer JH, et al. The effect of cricoid pressure on preventing gastric insufflation in infants and children. Anesthesiology 1993; 78:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/18\">",
"      LEIGH MD, McCOY DD, BELTON MK, LEWIS GB Jr. Bradycardia following intravenous administration of succinylcholine chloride to infants and children. Anesthesiology 1957; 18:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/19\">",
"      Sing RF, Reilly PM, Rotondo MF, et al. Out-of-hospital rapid-sequence induction for intubation of the pediatric patient. Acad Emerg Med 1996; 3:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/20\">",
"      Kelly MA, Finer NN. Nasotracheal intubation in the neonate: physiologic responses and effects of atropine and pancuronium. J Pediatr 1984; 105:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/21\">",
"      Oei J, Hari R, Butha T, Lui K. Facilitation of neonatal nasotracheal intubation with premedication: a randomized controlled trial. J Paediatr Child Health 2002; 38:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/22\">",
"      Fastle RK, Roback MG. Pediatric rapid sequence intubation: incidence of reflex bradycardia and effects of pretreatment with atropine. Pediatr Emerg Care 2004; 20:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/23\">",
"      Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126:e1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/24\">",
"      Zelicof-Paul A, Smith-Lockridge A, Schnadower D, et al. Controversies in rapid sequence intubation in children. Curr Opin Pediatr 2005; 17:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/25\">",
"      Robinson N, Clancy M. In patients with head injury undergoing rapid sequence intubation, does pretreatment with intravenous lignocaine/lidocaine lead to an improved neurological outcome? A review of the literature. Emerg Med J 2001; 18:453.",
"     </a>",
"    </li>",
"    <li>",
"     Yamamato, LG. Emergency airway management - rapid sequence intubation. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher, GR, Ludwig, S, Henretiq, FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.81.",
"    </li>",
"    <li>",
"     Schneider, RE, Caro, DC. Pretreatment agents. In: Manual of Emergency Airway Management, 2nd, Walls, RM, Murphy, MF, Luten, RC, et al (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.187.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/28\">",
"      Maslow AD, Regan MM, Israel E, et al. Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthma. Anesthesiology 2000; 93:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/29\">",
"      Sivilotti ML, Filbin MR, Murray HE, et al. Does the sedative agent facilitate emergency rapid sequence intubation? Acad Emerg Med 2003; 10:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/30\">",
"      Sokolove PE, Price DD, Okada P. The safety of etomidate for emergency rapid sequence intubation of pediatric patients. Pediatr Emerg Care 2000; 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/31\">",
"      Guldner G, Schultz J, Sexton P, et al. Etomidate for rapid-sequence intubation in young children: hemodynamic effects and adverse events. Acad Emerg Med 2003; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/32\">",
"      Ching KY, Baum CR. Newer agents for rapid sequence intubation: etomidate and rocuronium. Pediatr Emerg Care 2009; 25:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/33\">",
"      Zuckerbraun NS, Pitetti RD, Herr SM, et al. Use of etomidate as an induction agent for rapid sequence intubation in a pediatric emergency department. Acad Emerg Med 2006; 13:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/34\">",
"      Oglesby AJ. Should etomidate be the induction agent of choice for rapid sequence intubation in the emergency department? Emerg Med J 2004; 21:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/35\">",
"      Hoffman WE, Charbel FT, Ausman JI. Cerebral blood flow and metabolic response to etomidate and ischemia. Neurol Res 1997; 19:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/36\">",
"      Modica PA, Tempelhoff R. Intracranial pressure during induction of anaesthesia and tracheal intubation with etomidate-induced EEG burst suppression. Can J Anaesth 1992; 39:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/37\">",
"      Renou AM, Vernhiet J, Macrez P, et al. Cerebral blood flow and metabolism during etomidate anaesthesia in man. Br J Anaesth 1978; 50:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/38\">",
"      Bramwell KJ, Haizlip J, Pribble C, et al. The effect of etomidate on intracranial pressure and systemic blood pressure in pediatric patients with severe traumatic brain injury. Pediatr Emerg Care 2006; 22:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/39\">",
"      Bergen JM, Smith DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med 1997; 15:221.",
"     </a>",
"    </li>",
"    <li>",
"     phx.corporate-ir.net/phoenix.zhtml?c=175550&amp;p=irol-newsArticle&amp;ID=1518610&amp;highlight= (Accessed on August 01, 2011).",
"    </li>",
"    <li>",
"     Rapid Sequence Intubation. In: PALS Provider Manual, American Heart Association, 2002. p.359.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/42\">",
"      White PF, Way WL, Trevor AJ. Ketamine--its pharmacology and therapeutic uses. Anesthesiology 1982; 56:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/43\">",
"      L'Hommedieu CS, Arens JJ. The use of ketamine for the emergency intubation of patients with status asthmaticus. Ann Emerg Med 1987; 16:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/44\">",
"      Sarma VJ. Use of ketamine in acute severe asthma. Acta Anaesthesiol Scand 1992; 36:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/45\">",
"      J&oslash;rgensen BG. [Ketamine as a broncholytic agent in status asthmaticus and as an anesthetic for patients with bronchial asthma]. Ugeskr Laeger 1992; 154:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/46\">",
"      Petrillo TM, Fortenberry JD, Linzer JF, Simon HK. Emergency department use of ketamine in pediatric status asthmaticus. J Asthma 2001; 38:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/47\">",
"      Page P, Morgan M, Loh L. Ketamine anaesthesia in paediatric procedures. Acta Anaesthesiol Scand 1972; 16:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/48\">",
"      Wyant GM. Intramuscular ketalar (CI-581) in paediatric anaesthesia. Can Anaesth Soc J 1971; 18:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/49\">",
"      Brown L, Christian-Kopp S, Sherwin TS, et al. Adjunctive atropine is unnecessary during ketamine sedation in children. Acad Emerg Med 2008; 15:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/50\">",
"      Hofer KN, McCarthy MW, Buck ML, Hendrick AE. Possible anaphylaxis after propofol in a child with food allergy. Ann Pharmacother 2003; 37:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/51\">",
"      Cole SG, Brozinsky S, Isenberg JI. Midazolam, a new more potent benzodiazepine, compared with diazepam: a randomized, double-blind study of preendoscopic sedatives. Gastrointest Endosc 1983; 29:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/52\">",
"      Sagarin MJ, Barton ED, Sakles JC, et al. Underdosing of midazolam in emergency endotracheal intubation. Acad Emerg Med 2003; 10:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/53\">",
"      Salonen M, Kanto J, Iisalo E. Induction of general anesthesia in children with midazolam--is there an induction dose? Int J Clin Pharmacol Ther Toxicol 1987; 25:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/54\">",
"      Robinson AL, Jerwood DC, Stokes MA. Routine suxamethonium in children. A regional survey of current usage. Anaesthesia 1996; 51:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/55\">",
"      Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology 2006; 104:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/56\">",
"      Larach MG, Rosenberg H, Gronert GA, Allen GC. Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila) 1997; 36:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/57\">",
"      Gronert GA. Cardiac arrest after succinylcholine: mortality greater with rhabdomyolysis than receptor upregulation. Anesthesiology 2001; 94:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/58\">",
"      Clancy M, Halford S, Walls R, Murphy M. In patients with head injuries who undergo rapid sequence intubation using succinylcholine, does pretreatment with a competitive neuromuscular blocking agent improve outcome? A literature review. Emerg Med J 2001; 18:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/59\">",
"      Cunningham AJ, Barry P. Intraocular pressure--physiology and implications for anaesthetic management. Can Anaesth Soc J 1986; 33:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/60\">",
"      Vachon CA, Warner DO, Bacon DR. Succinylcholine and the open globe. Tracing the teaching. Anesthesiology 2003; 99:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/61\">",
"      McAllister JD, Gnauck KA. Rapid sequence intubation of the pediatric patient. Fundamentals of practice. Pediatr Clin North Am 1999; 46:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/62\">",
"      Perry J, Lee J, Wells G. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2003; :CD002788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/63\">",
"      Cheng CA, Aun CS, Gin T. Comparison of rocuronium and suxamethonium for rapid tracheal intubation in children. Paediatr Anaesth 2002; 12:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/64\">",
"      McCourt KC, Salmela L, Mirakhur RK, et al. Comparison of rocuronium and suxamethonium for use during rapid sequence induction of anaesthesia. Anaesthesia 1998; 53:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/65\">",
"      Andrews JI, Kumar N, van den Brom RH, et al. A large simple randomized trial of rocuronium versus succinylcholine in rapid-sequence induction of anaesthesia along with propofol. Acta Anaesthesiol Scand 1999; 43:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/66\">",
"      Smith CE, Botero C, Holbrook C, et al. Rocuronium versus vecuronium during fentanyl induction in patients undergoing coronary artery surgery. J Cardiothorac Vasc Anesth 1999; 13:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/67\">",
"      Smith CE, Kovach B, Polk JD, et al. Prehospital tracheal intubating conditions during rapid sequence intubation: rocuronium versus vecuronium. Air Med J 2002; 21:26.",
"     </a>",
"    </li>",
"    <li>",
"     Walls, RM. Rapid sequence intubation. In: Manual of emergency airway management, 2nd, Walls, RM, Murphy, MF, Luten, RC, et al (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.26.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/29/24026/abstract/69\">",
"      Ellis DY, Harris T, Zideman D. Cricoid pressure in emergency department rapid sequence tracheal intubations: a risk-benefit analysis. Ann Emerg Med 2007; 50:653.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6390 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7CC26F0507-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24026=[""].join("\n");
var outline_f23_29_24026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RAPID OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREOXYGENATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intubation treatment plan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Equipment and monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PRETREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Atropine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Lidocaine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Defasciculating agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SEDATION AND PARALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sedative and induction agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Etomidate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Thiopental",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Ketamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Propofol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Midazolam",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Paralysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Succinylcholine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Rocuronium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Vecuronium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Pancuronium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PROTECTION AND POSITIONING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Protection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Cricoid pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Bag-mask ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      PLACEMENT, WITH CONFIRMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      POSTINTUBATION MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6390\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6390|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/53/22354\" title=\"figure 1\">",
"      Sellick maneuver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6390|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/55/1908\" title=\"picture 1\">",
"      Pediatric position for ventilation and intubation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6390|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/11/12475\" title=\"table 1\">",
"      Rapid sequence intubation seven Ps timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 2\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/52/4939\" title=\"table 3\">",
"      Difficult airway children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/35/10812\" title=\"table 4\">",
"      Pediatric airway equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/29/36316\" title=\"table 5\">",
"      Rapid sequence intubation induction agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28948?source=related_link\">",
"      Assessment of perfusion in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_29_24027="Blood donor virus infections";
var content_f23_29_24027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70772&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of transfusion transmissible viral infections in first time blood donors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Virus",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Prevalence per 100,000 first time blood donors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        1991-1992",
"       </td>",
"       <td class=\"subtitle2\">",
"        1996",
"       </td>",
"       <td class=\"subtitle2\">",
"        p value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HCV",
"       </td>",
"       <td>",
"        630",
"       </td>",
"       <td>",
"        400",
"       </td>",
"       <td>",
"        0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBV",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        0.36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HTLV",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        0.10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        0.006",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HCV: Hepatitis C virus; HBV: Hepatitis B virus as measured by hepatitis B surface antigen; HIV: Human immunodeficiency virus; HTLV: Human T-lymphotropic virus. P value: the test of a common prevalence from 1991-1992 to 1996.",
"    </div>",
"    <div class=\"reference\">",
"     From Glynn, SA, et al. JAMA 2000; 284:229.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24027=[""].join("\n");
var outline_f23_29_24027=null;
var title_f23_29_24028="Risk factors severe jaundice";
var content_f23_29_24028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for development of severe hyperbilirubinemia in infants of 35 or more weeks' gestation (in approximate order of importance)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Predischarge TB or TcB level in the high-risk zone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice observed in the first 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood group incompatibility with positive direct antiglobulin test, other known hemolytic disease (eg, G6PD deficiency), elevated ETCO",
"        <sub>",
"         c",
"        </sub>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gestational age 35-36 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous sibling received phototherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cephalohematoma or significant bruising",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exclusive breastfeeding, particularly if nursing is not going well and weight loss is excessive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        East Asian race*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Predischarge TB or TcB level in the high intermediate-risk zone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gestational age 37-38 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice observed before discharge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous sibling with jaundice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macrosomic infant of a diabetic mother",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maternal age &ge;25 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decreased risk (these factors are associated with decreased risk of significant jaundice, listed in order of decreasing importance)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TB or TcB level in the low-risk zone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gestational age &ge;41 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exclusive bottle feeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Black race*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Discharge from hospital after 72 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TB: total serum or plasma bilirubin; TcB: transcutaneous bilirubin; G6PD: glucose-6-phosphate dehydrogenase; ETCOc: end-tidal carbon monoxide concentration.",
"     <br>",
"      * Race as defined by mother's description.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Subcommittee on Hyperbilirubinemia. Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics 2004; 114:297. Copyright &copy; 2004 The American Academy of Pediatrics.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24028=[""].join("\n");
var outline_f23_29_24028=null;
var title_f23_29_24029="Diff dx joint pain child";
var content_f23_29_24029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of joint pain or swelling in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Single joint involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Septic arthritis or osteomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juvenile idiopathic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyme disease in endemic areas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactive arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemarthrosis due to trauma or bleeding diathesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy such as acute lymphoblastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Multiple joint involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Connective tissue diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systemic lupus erythematous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Juvenile dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sj&ouml;gren's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixed connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Henoch Sch&ouml;nlein Purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Juvenile idiopathic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactive arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyme disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunodeficiency associated arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel associated arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic recurrent multifocal osteomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic infantile neurological cutaneous and arthritis syndrome (CINCA), also known as Neonatal-onset Multisystem Inflammatory Disease (NOMID)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prominent systemic features and joint pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Connective tissue diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Systemic lupus erythematous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mixed connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Kawasaki Disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Henoch Schonlein Purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic juvenile idiopathic arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy such as neuroblastoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reactive arthritis such as Acute rheumatic fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial infection (tuberculosis, gonococcal infection, Lyme disease, and Brucella infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral infection (Epstein Barr and Hepatitis B virus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasitic infection (Malaria)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel associated arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Autoimmune disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Periodic fever syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic infantile neurological cutaneous and arthritis syndrome (CINCA), also known as Neonatal-onset Multisystem Inflammatory Disease (NOMID)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pain without joint swelling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hip disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Legg-Calve-Perthes disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Slipped upper femoral epiphysis (Slipped capital femoral epiphysis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign hypermobility syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inherited metabolic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gaucher disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sheie disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Osteochondroses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Osgood Schlatter disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Scheuermann disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Idiopathic pain syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Growing pains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Complex regional pain syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fibromyalgia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Yukiko Kimura and TR Southwood.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24029=[""].join("\n");
var outline_f23_29_24029=null;
var title_f23_29_24030="Normal MAC and MAMC females";
var content_f23_29_24030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percentiles of upper arm circumference and estimated upper arm muscle circumference for Caucasian girls in the US Health and Nutrition Examination Survey I of 1971-1974",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age, years females",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Mid arm circumference (MAC) percentiles",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Mid arm muscle circumference (MAMC)&nbsp;percentiles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        5th",
"       </td>",
"       <td class=\"subtitle2\">",
"        50th",
"       </td>",
"       <td class=\"subtitle2\">",
"        90th",
"       </td>",
"       <td class=\"subtitle2\">",
"        95th",
"       </td>",
"       <td class=\"subtitle2\">",
"        5th",
"       </td>",
"       <td class=\"subtitle2\">",
"        50th",
"       </td>",
"       <td class=\"subtitle2\">",
"        90th",
"       </td>",
"       <td class=\"subtitle2\">",
"        95th",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-1.9",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        177",
"       </td>",
"       <td>",
"        105",
"       </td>",
"       <td>",
"        124",
"       </td>",
"       <td>",
"        139",
"       </td>",
"       <td>",
"        143",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-2.9",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        111",
"       </td>",
"       <td>",
"        126",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-3.9",
"       </td>",
"       <td>",
"        143",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        113",
"       </td>",
"       <td>",
"        132",
"       </td>",
"       <td>",
"        146",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-4.9",
"       </td>",
"       <td>",
"        149",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        184",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        115",
"       </td>",
"       <td>",
"        136",
"       </td>",
"       <td>",
"        152",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-5.9",
"       </td>",
"       <td>",
"        153",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        203",
"       </td>",
"       <td>",
"        211",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        142",
"       </td>",
"       <td>",
"        159",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-6.9",
"       </td>",
"       <td>",
"        156",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        204",
"       </td>",
"       <td>",
"        211",
"       </td>",
"       <td>",
"        130",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7-7.9",
"       </td>",
"       <td>",
"        164",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        231",
"       </td>",
"       <td>",
"        129",
"       </td>",
"       <td>",
"        151",
"       </td>",
"       <td>",
"        171",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-8.9",
"       </td>",
"       <td>",
"        168",
"       </td>",
"       <td>",
"        195",
"       </td>",
"       <td>",
"        247",
"       </td>",
"       <td>",
"        261",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9-9.9",
"       </td>",
"       <td>",
"        178",
"       </td>",
"       <td>",
"        211",
"       </td>",
"       <td>",
"        251",
"       </td>",
"       <td>",
"        260",
"       </td>",
"       <td>",
"        147",
"       </td>",
"       <td>",
"        167",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-10.9",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        251",
"       </td>",
"       <td>",
"        265",
"       </td>",
"       <td>",
"        148",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11-11.9",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        224",
"       </td>",
"       <td>",
"        276",
"       </td>",
"       <td>",
"        303",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        181",
"       </td>",
"       <td>",
"        217",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12-12.9",
"       </td>",
"       <td>",
"        194",
"       </td>",
"       <td>",
"        236",
"       </td>",
"       <td>",
"        282",
"       </td>",
"       <td>",
"        294",
"       </td>",
"       <td>",
"        162",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        214",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13-13.9",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        243",
"       </td>",
"       <td>",
"        301",
"       </td>",
"       <td>",
"        338",
"       </td>",
"       <td>",
"        169",
"       </td>",
"       <td>",
"        198",
"       </td>",
"       <td>",
"        226",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14-14.9",
"       </td>",
"       <td>",
"        214",
"       </td>",
"       <td>",
"        252",
"       </td>",
"       <td>",
"        304",
"       </td>",
"       <td>",
"        322",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        201",
"       </td>",
"       <td>",
"        232",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15-15.9",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        254",
"       </td>",
"       <td>",
"        300",
"       </td>",
"       <td>",
"        322",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        228",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16-16.9",
"       </td>",
"       <td>",
"        218",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        318",
"       </td>",
"       <td>",
"        334",
"       </td>",
"       <td>",
"        170",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        234",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17-17.9",
"       </td>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        264",
"       </td>",
"       <td>",
"        324",
"       </td>",
"       <td>",
"        350",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        205",
"       </td>",
"       <td>",
"        239",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18-18.9",
"       </td>",
"       <td>",
"        222",
"       </td>",
"       <td>",
"        258",
"       </td>",
"       <td>",
"        312",
"       </td>",
"       <td>",
"        325",
"       </td>",
"       <td>",
"        174",
"       </td>",
"       <td>",
"        202",
"       </td>",
"       <td>",
"        237",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        19-24.9",
"       </td>",
"       <td>",
"        221",
"       </td>",
"       <td>",
"        265",
"       </td>",
"       <td>",
"        319",
"       </td>",
"       <td>",
"        345",
"       </td>",
"       <td>",
"        179",
"       </td>",
"       <td>",
"        207",
"       </td>",
"       <td>",
"        236",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-34.9",
"       </td>",
"       <td>",
"        233",
"       </td>",
"       <td>",
"        277",
"       </td>",
"       <td>",
"        342",
"       </td>",
"       <td>",
"        368",
"       </td>",
"       <td>",
"        183",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        246",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35-44.9",
"       </td>",
"       <td>",
"        241",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        356",
"       </td>",
"       <td>",
"        378",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        218",
"       </td>",
"       <td>",
"        257",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45-54.9",
"       </td>",
"       <td>",
"        242",
"       </td>",
"       <td>",
"        299",
"       </td>",
"       <td>",
"        362",
"       </td>",
"       <td>",
"        384",
"       </td>",
"       <td>",
"        187",
"       </td>",
"       <td>",
"        220",
"       </td>",
"       <td>",
"        260",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55-64.9",
"       </td>",
"       <td>",
"        243",
"       </td>",
"       <td>",
"        303",
"       </td>",
"       <td>",
"        367",
"       </td>",
"       <td>",
"        385",
"       </td>",
"       <td>",
"        187",
"       </td>",
"       <td>",
"        225",
"       </td>",
"       <td>",
"        266",
"       </td>",
"       <td>",
"        28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65-74.9",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        299",
"       </td>",
"       <td>",
"        356",
"       </td>",
"       <td>",
"        373",
"       </td>",
"       <td>",
"        185",
"       </td>",
"       <td>",
"        225",
"       </td>",
"       <td>",
"        264",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Frisancho AR. Am J Clin Nut 1981; 34:2540.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24030=[""].join("\n");
var outline_f23_29_24030=null;
var title_f23_29_24031="Stage III lateral condyle fracture";
var content_f23_29_24031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81394&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stage III lateral condyle elbow fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 207px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwAM8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyVWw4G3689KuW7gg7lOe3tVKIbjkGriEcLk5FbATRkg4YcGrcLEKvTCnvVKMHeTnPPepopGJKnn096ALhO7ooBzXoHwYR28VAhQGVRn35rzrdnk8Edq9N+Bvy69PI3zKFHLdqQmfSdqVCYHBz0pl5IoGCT07VHYY5wcn19abckM8nmdBxj1qLaiuc/fTSxW0rgkkL1/HpWRNKxKyAmNNg+YcgGp77zi8kaY2McfOeg9ayr8iGMgybjx0OR+VWgI5UlQBc5kJ3ZPf3qrAGKSOxZAgJGCcdf5U83MsMczHy2JGBuqraSzzz7i4ZGXBQnHHpTGbMcqh4ZFTO8dQMYJ/pV21f98i7duMrgH1rPuWjgjiaAMu3Cuuf1FMS+3RGYZYc4z2qQLqy+UssPITDcZzk1i6qSsa5JUhc5NWPMVZfOR0wy4I+tUNRmRo+QwJXGcZGaQHnXjCEvps7fM2eVOa8zlDbcls59K9S8RfvbWVHcn5TxjGa8rkTaWHamMpzY3fNmoH4yOOfepZmyeM/WoJvXrSAhfGeM/jVec4xz1FTEBuear3PCZyOKQihKzADbzjpUEh55PWppiMZPQ+lVWHAODx0FIBk2e/NQSD5Q3YcVJIScrzkioGbaMHpQM9Chzjt71dTAO8+3as2JvnRsHn34q6shyFxyOfpWoFoMOTkrk96n2qqoq9c9aqIcqSRU6tnBAx9aALZjO8Dk9/wr1r4HwEvcOD0Yce1eQK7YHPzDpzxivcPgrEI9M8wld0hI3HvSA9qtH2Y25JPaq1zcFY5HVS3GTmnQnZtHXjrVe/LDYYznGc88UrEnL6i5XMkrFt4zhRwKw75yLR3QYVyM4PT8K2NaKxW7yI+WDcgjk1zN2zmIAbPm5x6CmA+G7HkNG3Kqdxcjk1dkmtbSytmhJ3NlsMM9TWDcbyiSkosbDac8Z+gqG41JP3PkphV+Q560xnTancotvCY3zIykkY4rPtJ0ZpC24BVIIz1qjPPNcPFIzDI4bnHAqZZPkY7c5OF54FJgTLKp06OZDlg+GK/ypLtj9kO1imWyM/yqrvH2domcKUcMe1PvJWEbgKHLLlWqQOQ19vmdXZWdgRx0FeXXxKuR025Fek67KPOJcAucgLXmOqOVupQBjBpjM+XPpzUUhwAecU6RjnOe1QseOuaTAaeVPNV5wSp9MVMxPORxUMrErxn6VIjOb5d2c4PaqzcjBOM96sTMM4wc+lV2G7nGPxoAilADAA8AVDMBjI5Y/lUzAktxhgOarTE8YNAzvowqnn8ParKDbnBxVdTnGMD2qZHORnB5rUCyMjAU8dzU6FeOcE1V9wc1JGzKMZzg5zQBaLhm9vUV9A/COPydJtlwuMZI9TXz3AokkjVcKxavpT4cW6JZwFcfIBnngmkJno8joI8v8o4zisnUX3Wx8sn5Tnn1qXWZT9l8tWUFvmHr1rM1C63RbVcncQOnoKCTD1GYvZlwNodgMEc4781hXxiW4CuAY1UHg81rS2s91xHIxTfyD/Ksv7G0Sym7jYsWwSvUCmUZl3dwGNwoZ0QZweQDWbHavcLG0ZOSSQMcCtgmztJtiCSRWJyG4A96rXN0u1TbHYMY4PQ0ASyqbd4kkjw+3BU9KlKJNAxdjlCMhaZdkXJ3yowfYAp7/WhbhYwtu/AkOMAc/jSYCmVfNkjEincmBlcnNMncNCg+Y/JtFZ9w7JcbkJAAyFPWnJcrsAZ2LHJAA7YpDOb1xPMlDL8pz0P86851pWW9dicgnOK9J1Z1ZI2UMxGSR6CvPPEn+sDY6igDFkU4bPb0qtIeMDmrDHK4JFVXwS2FxkUhEJY7fU1BLkDk4x2qdWCn3qGVueRkZqQKMoyxKnIHeq7PgkfpVmbjPPOelVJHGdwyTnmgBrkgnBwT1NVZCckVPK2c4qqck0DPQYyE9G96nj5JPGB3qFBhCMdeKliKgc8DsK1AsBlXOCOR0pyHAJAyvSo0KlwcYNPiVjkKc5PSgDT8Px+fqVqoX/loCR7V9OeDYs2qiPAIHTGOK+d/A9objU2ZdwKDtX0p4ZjNtaoFOSIx0FITJ9TuWa8Cld/kryuOlYt/dKsDls7mYBQDyKsa3dPHc/uwUdl+Yg8mudN2G3CQDAPJJ6mgViK4v5rVZo4Sd4YN1yCDTLzU7jzEE6go5HHSs+KZEnmZiGzz69KiM0075lDHA3KvqKYy5qUQdfNRR5bDr0wfaqkKW8atuwGYY2v2+lUTNNNC0JlIRjnnoMdqoSNPPcKVBdVxnmgDpkXytOkM7KSvKkms+CYSOJCyHnc3arDHEK+acbhwtZDyvukjBwvJyaTA0b5klnRojkqmeOlVA5dYmZSgU4PPNJG4W3jJKADPTr+FV3do4c5+YjqR2qRlLWQphlAJXDZznkVwPiNUAAA+VR1Peu71BxJauMDeQDn1x2ri9aj+RyyYz2pgcnIBnPWoHx+HcVNJycDPFRt0OePwpMRVcdwCBTCo25yc54qWX5en/6qgZuQDSAguQu3PoeaoyD5eNo96uTk7j16fnVGRtvUc0gK0hHtkDtUOeafIwYcdaYMigZ6LGo2qCTUwVSeByah2ttwCKkXqOQB3rUCZVJxjk9jUsOXyMYbpUcbjkAMAPWpIBudQvJLD2oA9J+F+n4YTy5CE845zivZ/ta2ml5+67dDnoK8/wDBFmIbSJYgNzgZIPSul1W4DAI+PJQ7Wx1zSEVn1B3ZmeTcc8E9AKxWneTECqNhO7Hue9OkYSMRISig529zWfIEjztB3dR/SmA9o2UPk4VSRn1FOtCUZSszEKCBgZxWczE/K5OcglAecVMt7tEicqo64GAaAGGbCNvZiA33dvFT744oFkOFXnEY61Xa722TmWLPz/L/AI1UE2+WQZGc/Kp5NAD7zVXnZOSu0ZUkUkBDEOM/N171T1JSuQiHcQPlHan2z7Y3yCCo4GaQFm6K5UqGLL3qO6YhA7DcoHQn9aqRXGZm3qA3cn0p0jmX93sxxjOaQwmCC3YAoSRvHFcxrkZV3Ynhhx3ratWa32pOeORx3rJ1PeVbjKJ29qAOEuEZJmGehqsxPJPPetPU0Ky9MZGazyu0YPc9aQiFhuOWGRVeQZBxirRXghT161XlwEqQKsmFUnvis+Zmwe3PetCVdx29RVOfkgcZFAFBz82MAHv2pCuM/MBU1ymCMd+1V2Ofp6UDPRwQeB1FKAd3HfvSR4DdMHFSZ5+h/OtQJVAxya1fD1oLrU4VJGxTk1lxkNkgDmuz8EWWSHZQS3IoA9U0FRFab0+ZVHyt9KgupgFbz1+bfuBz3qSPy7e0hjUgqfmIPesi7nVYn8wYJbIHWgQXFw0jsyKVboVx2rPkmP2gno5PQd6dFPLuk3DbgfKKyvO8y4GfkfdwTxwO9AF2KORXMgAfeDuPTFNlnaGFfMID7c4x2qHzpH3xgoDIdqnJORUk0ckMLR4Uyhcc84FADICLuR0ZgikDaxqG1jKXkpOGCZUN0NT6ZajUH2NiNFXczfSrWsTW0Ue20EZVcc568UAZF7K6bSzg5yc1XgLwss6fMp9abNIt1E+VAK8j1qONiytE4+Vf4c9KQFmbdLPv5KSdCO1EaLKXhyScZznqapySGJiqFgARwOmKntpfJmlkzn5ePY0hle8YxgH5eDiql0DJG+0E5681cuSZlEgUBWPOfX1qgrxksjHJbIzQByurBVbPOF4H0rJfpn2rotZRQSu3j+HNYJX5eRyKkRWOduB16mq7nBIB4NTyqdzYz71AVH1x3pAQvgHrxVG5Q781oy42HBGfeqUvJ2t25NAFVvmBGOnrVOQAH5atnHQjHpVaXAYg84oGegjGe+CalwcHjHNQoPmyRUuGJxng8/StQLNtHveNV5LHBr1HwnaCHldpXb0PWvP9AgzMZCNygYH1r1LQrYxWkbOFLnoB2oEaczusgDKAAnCj0rClYZMlxltzfLtPQe1aN1cv5aDa6hifmasqdvmjGQxzyOwoAk1CYxzeZEobcRkk9Kx7ub/SGaQEt0XHHFXbxVkuXcsdmQoVRwPpVO7SQXXzEFQoAHUgCgCaWRYnCz4IAGPanpe5Owxrg4zJnkVVZRLcKrtliNxOeg7CoJ5fLllwNyjjnj8aANIs1lbXNxBu5yAPr3rMLi4t2LjBc7ev60mpXrNpkaoc4+8D3qhauTGrSBfLHGFPegCR/wB0xiiDcck+tSwfOjeYpDdQQcfnTWZrhO2O/v8ASoYisdk2VYsxJAx0oAeeBIQOvFJEQzqrZ9WBqJS5CMQ3TtTpGVVLYO48A0hliYhoQAc4OOB27VkStwNyfxcHOK1bcMz7WC4Ix1rJutyFt46Zx7UgM+/BZ1Y8r6Z6Vz9xxM69s10lziSMgckjcCawdQTBVh6c1LEZ8i5Gc4zVc/T3qwxJVtwOKidsj5MA9MUgK7jJPOSetVJ23OFUZzwTVpyQTjoagdMfMv5UAVJEY8d/SoJIstyQDV5snPABNVpgQo6DNAzuA+1sdsdPWnRuS+CvPb3pqkdeM1raLp7zzLLIv7scj61qBveGLJvlQ8M44r0CCVba3SSRgEQYIHXNc7p2yEDAwAcgkdTWq9zm6EOFkRgDu96BD7u7EsAlUkYPCntVZwixo8YHJ5B9fWoLycxyFTukzwDjqafcbgqIEwyjdgDjNACSnzQAJBkNk+hPtVIoWcl2IIJLc9farqGQQJvRI8tkqB+vtVe4mWKJ1ARnQYz1yTQBmXFx8oUJtGeo60MI/s/l98ZznoaVcFXmkwQOqkd+1Vpmcg5QMSO1ADLsMlsEZGbI4PrVeCQCwljEY3bwc1YkeUDrgr0IOaqWpVnePkh+pIxzQBYiKrbgEZfsOwqwGZo9jpkDgc9DVMjy5zHJ8qrypxUo8kxPuYqxPGeRn1pMBzBtpUcbupqpczOF24yDyuBjFSj5/wB2CQw/WorgnjKAcYPqKBhA7edCQyhTzz3NE6mcyphRKDuU9mFRwOrOFc4APp2qS9Xa0flfLgE8HtSAyUb5cFeQOtZl7HuVyOinIrZZF2ggfKe/pWddo2QCcoR2qBGG4AHqagKjH3OankVg+3jIPIphTrQBTkGD6VG68VZkUFvpUUqkAUAViobNVHU9M89vSrkvTGOtVtvPT86RR31nAGILcsTwBXV6X5YtvKkODnjjvWPaRosiq31yOp9q2bQIWG/CqnTJ5rYRs2z+bMf3f7sAKS3erVsZJJZkijPlBdquOo+lUUxLIkPITbkj1qzZpKRhiqIny4VuWNAiZCuxUVwSgPy4zmr/AJjIoQAYAG4jrmoLaCOGVhkcnOD2NWSiqHeRkAC5GO9AGdeRyO5RVZVIzvHHNQSwQx4RmAkxl2I6U+9ndZw0asI9oOPWqEl55tw7SMWXbyOgoAZNKMYJLknoRxVUzb98RBRC2SwqzO8LW6lVkG0456VQmZEYKX25+6aAI3RJEXluvGOM0jRmKNZiDuVuD2Ip02SEQOGBGc+9SuNkaKz8EgjHIWgY3UYY3vVaGbKhAXBHT6U0qkrbIjlCMg55qxcGMyRuF+cgKewNRRuI7gqQu0/jSAjaN8RsoQFVIfB602MKY3WYlnTnA9Kf9nkUyZO70IqWzhMkLRyqQwz8x70gM0LGS6t8x69ccVIGVxwB5iDtUlxGoPmxZxnGMd6gZ1WdjtxkDp3NIClI5LsuML1qtc/NkLnZ0yRV6ZCZC42gMMnFVUAKSITkHLKPepEc/eRES7lJ5H61WxkYIwK0bxMKSSSc1nlcH2oAhlGACBUDqdwz09KuEHjpjP51BKmGJpAVJVx71XZO/Iq5KQOMc1CI2chUGWPSgo9LtG8qZcDcX65rf0+2Cu29QWHJB7e9YloQJFYDJBzj0963opQuxlOSw5Ld62EPZXmnKRAhJGHzkcKK2bCxjYLuYuEOcqetZ+nzq08YJJjBwB2962WvFQvgBBnAVRjNAiTVZIrdRkbTjJI6isie5SXO2UbsYyV4x/jWfqVzukkJZs54BOeKoXNx90Kx2lckD+tAGnNcQxyKx3SqoxnOM1nTurP5i4RSOcD+dRQzCNSGVnXOB6D3pjsHe4Z8opHy0DJI282RuR5OeD61JdiNjvXcSRjB7CqwMkYTlQD0Xrz61PIxW3GJDuzyMdqAK/BTCdM9xn8qsyI6GNXwCybgarRuqo5JxnpSzh3K/N8oGM0CLUm2Sxj+bIRs8Ux4T5q8YVhkE+tOjO60JwFLDb04PtUqhwVjVQ+B60hkUaSKx2ZLM3PPFTTyNG8qy8q68exp0ccu8EEKD1wM1HOC7qC456k9KQGc25Yg4OQpySD19jVbY0iu/wDE3QnjFXZYwxmwDtccHOMGs9HIUn+78uCe9IAjOUlEhCsmAB6iqS5VsnBA6ZqQkKDkbjjJz2qKUcjg4IyoPapEVrtMu3G3isU4DHcCMVu3YJhDPy2cH2rGuVPmHaDg0ARDGKhk+8fQVKQRUbZXIzzSAqTAF/eoosi4QqcEZ5rRs7G61K8S10+1mubmTO2KFC7NgZOAOegJrPkQhj2IoGep2qRo65cHtkDp9atRSyJuGdzv93joO1ZsLsG2Jh884xVxpWEaJETvxyxHb2rYDrNNlg2hcAzBMsSMAH2qrqVxGm+QffDABenNY0N4olYSSFj1C9Ca2L+CO9gQW0iicAyOnpQIwZp1khKsG3byc+tDhJZVCyFMjH5VnzGWAqrjaQTw1LLIfOBBwAuAM9aBlh0Zdik8kkrUZk8tmPZuDuHANM892VE3BeMA1FLPlGjGDzzmgC7GzC4Dq2VA44qWX5QCy8deO1R2UwQhtud64A9KuOE2EMWyegz0oAoxOCvRcj5R7UkUoSR1IO3oR1BqWWIfd2hV5GPSq6xsFBRuPvHNAGlGytF5QABPTPUUxTjeBwQeOccVUjLszlc5zgGpnRt4ByMjLFhwaQF5D+6Zg53g4UE4JzRFCZmwvDIMEHoabb7YthkDSKeAw5xVrcWPm2sZBPyknikBlX8axRnK4BIByehqlcoEfABwRk+laV6pmBEYZhJ8x/3h2qgJTKj7kIcADHpSYGfcR/KSp5J9KikZzBjap2nt1qfzCn7zG5TkEE1UkIVgMkdyMVIhZyHwD068VlXyqWBXoattISepGOMe1VLg5OAQcGgCoygZwODS2Njc6pqMFjp8Dz3U7iOOOMZLseAK6LwF4XuPF/i/T9HtwwSZ8zSD/lnEOXb8B09Tgd6+sfG/hzTPD/hu91fw+NJ0XWrWxFpb6jcqAI4wAAuf720bQ2Ceg5HFID591q+tvhJok+h6FPDdeNb1NmpajHyLFCP9REf73q39cbfG2BPWrVw7zTNJIzSO7FmdmyST1JqKQADpg5oGjt42Yc9Djr6VcWbYu5wCqjAUd6zFG1CUbJYZH51YjOO+WJwOelbAXkZfNWUIG3nHXoBVq1nIlYIxEnbtgVmTyqjLuBAU4O2pz96XymIYkYPfFAG89mNZRW3rHMgwueN1cvf28lrdvHICrp61pR3Esd6pUnCrwe2a1HEetwrHdNFFOgOHPc+/tQBym/gnPzY4qJtxIydue9W7qyktpZFOGA7jnIqsUbYrKD83AoAu2UmHC54HpWnEVYryFweARmsa34mU4IY8dOtaIxHGr4yWPSgC00qZ2ODgdSD1qC7CPERbjAAG7Pf6VH5qqhjfncelRksS+zJOOAe1AEDsWI+YK3THY1cSZ/OiU7SdvOemarL+/bdhQy8kDtU0cLS3ccsWcIDke3rSAtwGRZWRvk44B6VcheWMMFcnnIPUYqC2aR4nBVjIWwH255qSWT92d52qBhiB37GkA+dGKq0HyqzZ45rPuhhn2psBGcjuaWK8lhZMAFQMrUd5OfNbZISjDKgjP4VLAxLw5K4AIB5NQXMxK8DA24qzOQrspwFPIx3rOkyR0OKQiuzkmmOS7ZxxUpjO/HO2hkO09h2yKTA9T+GfjDRfhv4audS8tdS8UaiNkcCHC20IPAkfsWPzFRk8LnFef+N/GeueM7/7Trt60qocx26fLFF/ur/U5Pqax3BC9z9agwAuRmgZVbgHr1qCU4GSeKsN16ZFRSj0GTQM6yPbxjPXirIciZSAM7c4HrUULpJgLgHnr0p8BJYlgCSefbFbCJYXzJtkG4sTk1Ms22Q8ZLHHHaq4AL724AHSrEezYoYqARn60APTetuWXLA8nB96kjJXy3Hc9KWJfKjlGdmcAZGc0+KLEjAP93uBQBbgJeUoT8p+Zjj9KjVEAcFVzngdaXytgYiT7wBIHaprdEVTnBLnjFAiK4gjSSN9hwoyquO5p6orKAyqu75hU8jqysSp3DCrk54pWQrGr7NzK2OTxigCuI4Q0MxTeFPzKT3qIgMJy0e1nbKFfT0q2n3mHABYHBGcfSpIxG0crEB9pIXHGKAM6K23x5CiNyeat6fEYpCFYAkfMemakbCMWkVgzLkZ6VBFKVfdkSL/AC+lSMuXMx3xRI42A8noBWb9oi8qaNn3r1A96WecKwwSOckdqoTEPISWUFm5HQAUACOPLyDgA5B68+lJPcSKwdyquOox1pJlESgDqewNNYbixc7sc9KTAr3REqb/AC1BJ6CmC03KrYGD2Jq00W9OCpGeuaYFZAec4PepERR2AAZ5PlX+lR3MKKPkcZB4GOtW8lhtJOOoU1UlOTg4AHGaQGc8WWOTn2qnJCyEg9fWtVtg5IwenFQnDkCkMx5ExyB+FVXGGPBya1rxADwfxrMlXP3jTGaySsgzxtrUtLqJo9srEbs1iowK8nn0p4baOcZFbCN52K/6tgRjgntU2f77bs9/SsGG6dWwSCvYVox3UMihdu0n0NAGrCysrqX6EHmrluNqIcqT3+lZUPlnLKwI9KtWkZWQ7W25HY5oA1AFV1JIII71JIUMKAtt25xiooF2qd67l2496sRJsRdyoI2Hf1oEJLEA3qDjp1HFBRxCBsLITndmmsJAXeOVHPUDpxVa4vRAioTyAGIoAvTMI48NtXHTHFVZbm3WIkHk8lhWPPeNKSecE5qo8hK8de4FAGvLeKWwGPH3cnPFV2vCuNind0BFZplIXJJHaneYxCleuelIZZE7NLyuVx1PanKxJ3Fcg8EnvUSSAyHAH0FSuxjyZG+8Pu470gHAnAOwAk8Fu9SIEBCcMx5JB6H0quXjLl8Px1zU7mNmcoTtIwKlgRytncuMIODt70mwsgPOc0wyAMBwCOcU4OGHzN8uc4HekIbvAWRmIGTgA+lVblCq4kOCOeKthVyN6jYuWODVO6lJIBzluaQFeQememagkBGM8GrUpH/1qqvg7jnj0NIZDcJnGBkVmzqQa0nZguc/L6Vn3TAyE9frTGLna+B171IjHcwPfimiMnBYg9+tOUYOTnNbCHL37Gp42PHQVFg7gBySKnjjJ5Y4AoAlhldZMLxVy3mnWTIfB+tQIgXp1P61ZRCZVwN3t6UAaEMsxTJkb1470SXU+3aJDj09KcEGM4G88c9KT7Pwp6qTgt7+lAEAvroSYDNkdcdMUwyvOX3Mc+lTmPdc/Kvy4wRUU0O0EoCB0xQBEThSSCRioS2XDc4BwKCrgYzx0GKjkfO3npSAeGaRsMQKtRBooumSTk+9Zxzv5GAK0ogrKoLlVJ5J9KAJY4dz5JC7h+VNcMvyuM9sk1agiSMOY28wDJUtTmMcyETpswMAgd6QFKRU+U7sKPyp29CrbchajuYyhUE8Y6AcGopQdi7MEmkwJQUXC9H9fapAFV938WMAVHGvdsbvSnMSG4BMh6DsBUiGzAtnceDxjNMMq5GFBAGMn0pZiS2FA4HUiqzMNvLYI7+tIZE5OTg8k5NRNwQKkZjv9WPf0pjg7uOuKQypJxnPQ1RmIY1eukOz39aoMoycmgCWLJ3cfL3q5CgMa9enpVaNSDjjmtFE2LhueOlbiEWJSQSDkd6mSNj8o4HXNLEg3HrgjjFaUUJZYvLGWHXPFAFa3hG8B8sFOcetX7O1ZgxD7MNUttGkl6FO2OQNgHGRWxd2jeZtbGeWB7GgCiYWSPymhUgtw5POana1lxMuxfLiAIOeGJ9PerFlBbyookmeSUv8wA+6KsvaeSIGmfgMDGBnke9AjGNrJlSDgnIPtUFzG8e3eBz69K2sBDM+1mWSTCqR1NQ3illiTA3sTldvT60DOZuYPKYlcE4z16VS2kyHaOvaugltTvAdTyMfjWROiGZwMgKcUAVCDk1btvu7mxgHgGoh3XGPwp8bFVDHk0gLoMhYZYAdgR0q1NKzxqpAdunFQxASKCgO7HY9KkhVQDuO055PWkATorAcENjjPWqSAkrxyTyT2FX5wA4GT0IJ65qrGnIVNpye/TFSwHwxjjDKBu4x3FSGJU3lwWYrwV6A09I1iOFOMjnmiUkxY2gY7dz7mkIz3DKMHB9qruAEYE5Pb3q2eGzyxxzVYjLkgHmkNEBAIBK4OPWoZOFJ9Kt3G1Mc5I9Kz5mJ+8TjtSGVZnDcEdOmKqS8n5eKsSYHHeq78kiiwF+Ff3qDrz0q7J908ZwcVDaxsZNw6YxWiVX90FUscjOO9biAcNs77QRV5ASwZGGVUDFV5lUXT8HGM5qzDC32feMqSeB60AaVnBHctH5S7XQHzAfX1qaJ5JrpIi7FQPwFQWCSxrhUKFhnLcE1oQWkc0QMhMco5wO9Aie1WV2EabBKwwxBAyvapmmmlwG3+ZE/zAjgAVWgtoC0k6y7ZUIGxvT1q3G0rSXiyyHcVBTjGc0AMZ2mPkceYX3o2MfrSZkuy3mYSXnAHHNSTrFJDuiVg8YycHlfwqOzBEhVTkt8wZh+lAFG5iIVJJFJCIcn0Ncs672YnoSe1dtcQtMs7RngDBFcY2Nr5GDnp7UDK+3yxk5Izg4prnCgsTkH86kzvT0Gc0zGQTnOTxmkBJDMyyDBYdjxV6K8RQWUrgj0rObGGOSM8c8VJFEAuQBn3NICzdzqynbks3f0qC3cxkruyMdPSk/DFKEGSVwO+fWpYE7XOcnhSOMAVDJcHdkMRnof8aGVtwJGCe9RSpiU9CM5B9aQh8s7FyBt5HSoTIw+QPzmnStlOB3pjbt2MZ9z1pDK0hzySc1C2SvTmp3Vs889qjZCFJHQcUhlKYfexVYjjJq5KhIODgVAy4GD0FAGxbfKBgZ9a1LWJpB8gw2f0rPijIXccjntW9aW7si/N8zHgjjitxFB4nVmZ8kbsNitctj5RhzgYB/hqw+nLIozN8obnFTabpQlczSeYqKSWOOTjpigBtwJZhEWY+YEHy47VatImi8uVjg/dfIP6Vd+zRW8rSySllKhSCO1alvarMkBi2OobPzdxQI52O1EYmJyZGcct12mn3m2W7dQ5EquCB/CABW1PYsr3U0nzSJwm3pntWZJaHLmU7Gbkk9s+tAEJuGW5eZdsgC56Y3VCksn2pJGQ+WW7npSJboLCUTOyyCTCjPWpbCMO7xEkrtzknpQBckkXypmEWWZ+GPSuF1GJobuWE/fVs8V2D/dVfMyC2MCuZ8RR/6Ws3J3LgHGCcUhmSMBTwevftRgZzxSZJYqw68jPWmr8vzDjngdjQBZG0rtx+NLE2Bjj1yahydnf1xTkyACM5x3pATFslMHk9eOKFAjOS2c9OOlNjfMnUliKTcuDk+1SwHdiS2TnmmlfM+83QZqMyjeccDpStMNw2nHFIQgOQC3amFi3QfL0OacfmOSc8dqifjBXJGKQyNzyMdKjYgc46+tSHBHXOBxULsMZNIZFIw2tjFUpMn2q3Lt+vtVSQ8njFAHWWkQkQq2eo5IzkV0Nmkcl0jPHwi/KM4HAqqsflISgG0OAGA6+1b6xrKWd8eao+XHTpW5IlouywLtGWZ/nVgchQKD9qXTDNcO6l5Plw38NPt7bbZx24b58NkKeDT7m1kmtkijXG1clD6igBkk3nxkBo0VcYdu/tWrG/mLDs8sMExgHjJ9KzLC3MlnLHOwEeMbvWnyMjQwmNQJB+7BUfrQBoxXCQSOHJKYwfTd6iqlwAkah9uXfGCOSKjuQ80ewxlUUjgfzpt580VqQGxGSxJNAEcsUfLlj5YbJUjpxVK2IUOwO7A7cZq1dXKGRyWwso+VQOtZySE28h24Y4HHpQBKzIzBtgXbyBngk1kayjS2TkAAocgjvV+4lLIhCBcH0xUFxIrwSZzkN2+lIZyZDAZbg0pb92oXoOTntReOPOYDOO1Q7mxx+NAE64ZwST6mnLIN5ycelVircZ4OfWkKncTnB60gLKylTkfezTCTnL8knvSABmwD0HenFenOFIJGalgJjcxyc/Smr3yMkHijPQnJA7in7QOhJbvSEBYEZA+b60xzlBzyKVgCBgdO9Nd9qjv25pDEjZcEnmqszDccrgVI3oDxUMzc5HOOKQyKV+AQRmqbsc8nNTyjqTiqsmc5oA9etYy1tIGQKitk46//AF62tPfZYuXYF26Fl4qjpytJZeYkhJ2ngDpV+ySRYoxLhlGccdD71uSW9HtFjjV3PzElsLzinfZIQWjZmJJ4JNFqxQxjADcnjuKkjxNMd2Dt+6AeM9hQBBptooleIkbWBwhHSo3jSJDaBMMnJIGSK0oYmjuvNKhm4xg4784qtdGY6lcSbsFn2IuPagCuYh5TiMlZcZIJyCKq/ehaNiSrDBB9atyzjyiyYkZBtJ6c1mSzebLmRguyPLY6UAQRq7qYlCEK2QxGcH61BdI7TKm8FmTJA9at2WfKuZTkpnORwcH0rV0e2Vg004BVUyrHvQBiTWc0kK+XCTnggms+5spgjRtCcgZUjmvQISwtlCIoQrk561VaJZgQiYZvmGe/rUgeQahZvBNk8Z5Ixiq7qB90DgZJz1r0nXrGC4+dkGGOPcHHSuWutC3O3kknI6Y6UDMEKHZgOnenHG4YUADjJ71ZnsZ7ZAHU7c8EVTYsx28cdKABAN2FAye5NPkLBh2A4OTTYnKrkEc8YxUjBWPzcntzUsCAttHU4oUqN+cdKVuwYYphI3+3rSEI8hKgDHHeopOTuB/CnOT+AprAfgaQxjHABOfaoWbnkde9PPynBORjAqBuvHSkMgnbB46VUd8AkdKnlOTiq7L2PTtTA9r8MyR/ZmTBLEA4zWq+/BG0AsR1Ncx4TuGYkHJwvU11DxGdd7jk/d3GtiTSt4g2oQtJt8tVzJ78dKntI4Zd86x+XCHzkdRjtVOzGzcZDlmIyewFaDsbXciqGiIJJ9/pQBZSb7VfRNHGhhTOVHGB61m6nEymaSEbiCSG9K00GSjDPlbNu4cVFrcQs7VFjKmRjuJzjIoA5u4VEjjBYB5TnaD396oXUYWQQP5amQ8+uP8ACtm4jiuIbaRsCRiduOvFY19AS8twMSbVIOTzQA6zRVgm342n7oznOK6HSoo3sYyoYoo+oHPSuWtbd0tY5Ru245yeldXogRdMEnzYLYAJ/WgC3JMVhfeD8ybQopmFjeJ3ZtwXCe1TXkMex5ATuX7oz7VWhcrEzv1TA47CpAz9RQEuyKmzqc9z71kQyfOjlVDFSAg6CtHViEkKQH92SCT657VkyPIC8aKAOisRyPagYSxodyttcDnaByBWJf6MkqmSEhHUcit0f8fIJDGbZgemaa53qyynAIx06UgODlt5Il2yYBBzn1qIoWlJBwK7C+sYrmNiysoAwCB1PtXK3sElnKAV4yQCe9SBXkYdMc1EcHqeaHJxheOc4qMA/eYEE0CAnJz3zUbjLipQeeKjyC+M4IpDIJOHPr2pkgCqQeBU743Eg/nVaTLE5PFIZUkAzmoX6c9Kmk5aoZCFPPIpgepeGwu2IYHBANdtEEkVVk4OCAa4Hw3uJXfklACB6139kzSxMVjww9eTitiSxp0eQ8LqQifNmtGbM9xHgEkjnsKhtVFvFIyA/MAOR3pr3HmIwQjzFfacDoKALDSido4Y+iyfdU96p63CZLlLiZ8hHK7V96t2sEh8rYCgIJLY6Y96q6ikYtl3uCGbI2nuPWgCrdMoazRZckKTwvQVjSIBasIn3b5Dk5/Sru7a6nfjClenY1UkeKOGIDJ2knpg0AUJ3YkrnaMYGeleg+HbZG8O2sjHPzdQOteeSB55S2eWyOB2r1Xw/CY/DUAwBJtHXvSAo34j+2gRnamzOCKyzIGEiMqhmGSK07+BYrjczH7gyqnqayZwNsZcKnJGSO3p7UgMXUdkjR7iw2/d56VmTPgMxbDuw2lulWdSPky5Rm4Of/rVWUCRGyoznJDCgZLI6rIz71Bf+dPTLoqKcM7Y3YzTIojcCMeWNqjJzVu4xptq8sjAOAccYxSYGdqWLceZPJtHIGe1chqt2lxKSv3RyPU0mr6k985diSATtANZT54JYk1IClxjIJzSbsjuPrUZPzY7UMctjdz1oEI5yNw5xTGznpTmJHSo3k7EUhiO2GwTVdzk5zU0hG3iq8h+U0hleU4+tV36cjmpnIPPeoWYHPHNMD0Pw0wyC249OOxr0jTwWXcCRH0wDya828NgAoGI616XpKsturEEtgYAHWtiTXMinh0b7vA/rVLCBVVWILPzV2BmMbEEb9hBB71juwTKjLE84HrQBdnu5AVgV28tRjHTJrK1ORwmIzg7h+GakfzHuJJn+XaNoFV5RvYNIwVQwY4Gc47UAMn2K7whyxCDnpiszzwJ9rpnbkZB/Wr7obnVA6MoBXAGetUrnatw6FMsuRkHpQA/TbczXCoykE9QDz1r2IxeRpjIFWNAqhB3PFef/D3T/tep+ZJkJEOTjmvUb9F+wvI7D72FA649qTA4nURsu2Zgx+XlR0NZF6pkhDCMqFOcE9Qa6K/VZCz7txc7QD/D71gantjtDnfkHDbT0x3pAc3cOHkkULhQpGz3plsH8pFWMNhTzT/MUzu0HU9Sfer2n2xZkxzs5bB9KBlqwtzb2PnnI5wOPzrh/GGpM0pthISOrHufau/1m58izy2AFGSBXjmoztc3DzPnczHGaQFNiSc8YFDHkDOf6U3O5sHqPWkIO7np3pAJIWwcYJpq53fNgU0HDEHjHQ0u4MBzmkIGPqaiZjliMY9KVwCc96hz19aQyNnA4xUbknr0pXBAx+VRuSODQMjYgnk1A2dzGnswB5HNQkk5JH4UAek+GgpbaQSM9q9P08GJVX7uVDAE15v4QTdIFz8u8Ese1ejWEzeYWAyvT1zWxJopGTFuYDbJlQx9azZIUHBTJzjr0rXTDwANkAEt9T6VTKqkbqg+Yndz0zQBRmieUYDKi7hznAqGdPLjnjABJ43damu2aSGJS+7MmScdqju1UpOF69z60AZMEQllWTdyg28Cn+UqzGQLnJznrz709WEWfLUgkAEEdDU8Vr9pljjG5S5GcHrQB6V8P7JbbRzKwUSTEs7dMeldDfwpI6Qk/Ko3bqj0ey8rT4Ywd21RjNXr5U3lnXlgAMdalgcdf2yK5kRR+755GMVyGrqxjAcNhiSff0rudUx5Mjn7zP37iuR1wgRlT/CuTz0oA5a3hGWAJXackD0rotHAYMSAFYcHPUelZVsn7lyFDF+PX8a1rZZI7REA5IBJA6CgZzfjecx2UzKw+Y7RXmciHuQR+dd18QG2iJd2WY7sYwcVwjjBcY47D1pMCE7d1R85I7VOMDIHcfkajfHyjoe9SIYx3duoqIDauRnrj6VKSSpDAU0YY4x8uaAGEEEnOO5zUUinO4EYPep5B8wODiq8g65HSkMiYHJ/nUEi4BzU7sOMVEeQaBkDLlRnH1qCRcHg1Zfp9agYDd60AekeFi4mKqSF4zgZr0jTjnYGyW5rzvwhk3u3rntXpenKIoeAA5J2k1sSadvhYGHLAcj2qK7TbFDlipc7j9KmdlEEik7SFyec80XyLmy2gMDGAec/jQIypUSQKoLbMkn3qrKFSKUEht/NW7hozcnBwgHSqcmPNChgMKevvQMicYjTBVpO5649K2/CVqb3WITJtxGctkd/SscR5t8xFdwOOnP1rtvhzY5lLlAzltzHHTAoEd3JIsewZ2hmwAoqvdMzzqxYBApIU9qtIiSK5PLIT0PGajRPkLNjGDkn+VJgc/qZR5I1cAlBnHSuC1RmkNzKcAsduPWu21UoguppHJj2/KQa4HUHRYkAYsWJIIbqKQyKKIRW6uByDhQD0+tbMaEWzMWXOOQTzWVAjRtjCkBM7euTWkgRYI/OXBc9PegZ558RHP2xEAHSuOcbkUkkKPWun8b8a2c5KheK5qUZAz0PSkBCACB0yDzUci9857DHepSCowMZ65phQqR83NSIgYHHBHvSKMYzjNPC5IBJznNH3cfXvQwIWwQT2zUcgO3nGakyBnJ69Kik65HWkMqyAZzmo3OOlTMp6YqJl60DIWHHNQSYUZPWrL4A4qs/zHmgD0zwpIIr8krkYr1LTHU2XRQQvGa8t8Lvi/C45Nen2BGABFnOOa2JNtEVkZeD+7AJHOTVfVVKSQlMIqJln9TV+xVT5mAM8KBnr65qpr0hW3mViVeQhQR0xQIwYofNChiFlY7mJ9Kqyqu9mLb+NnpVoMzOT1YAKAOuPWo7wpG8YAGSOee9Axi7N3lqpycKD0xXq/geAQaY8oIAPt7V5vBBC10m0ZQgM/0r1fw5HjT2Zeh4AIxxQJlhPMbTGxtV3brRehY7SUOTjHU96uRRnyApxwcmodRUmE7QCpGDmkwON1sYsUTy1YEA9K8+vsC6x5YCqcAAdK9G8TMIQHDk7SFwB2rzpyHu5pgFKgnOKQy5auqnAYKxH4mrMrEorcZA796htQVYEIGDDOSO9WL0hk2+V82c8H2pDPLfFrbtUcPwcZJPaudkUHDHPrj2rovFbH+0ygAIHUVzcuQ2QPm7e1AEWwhjjPPFEhGScdsUMzDg9+T71DIxc46CpARm+bNNzk89accDjqAKjHHXrQxDW54I+lRORg9fxqV+V5496hZSScntSGNyAOTjiq5PHNSke3FQuDz0xQMgc4Y+nYVC/wB7FTsM5qBv1pAekeHF/wBOAdtpxXqml4DwcEqOTn+deVeGQG1JA4H4163pgYtEpwEA456VuSzotOhDxZY7Cz7gaz9ZiE1xIo4Cn+Lv71paUF2MsjZZMYyPyqC6VPtEobBCp+JJNBJzT24E/wAnC+ueTUVxArxtKD90E9K0tethaosmcZ5AB61nbAUQbiAV+bJoGWNNjzLA2RtcDdu7+1e1aTGBp0ACYG0GvI9IjEQIwHQDjPJGa9i0MeVp1ruGSY+maTEOOAuR0b9KzrpmkjGBkluM+lbDRAQluAc/lWLqb+VhlY4HBAFK4zjPEZLF95G5FJAz1964JlxCdmMO21iPWux8US8SnaR8px9a42B9skaEAH16gmgZqLuYrtdflTp60s7MI03kxgjAOOtMsS3mszEqVUgqF7Ut0C5VWDfID1PagZ5d4idW1S429mwCe9Ychw2cA9zzWxrgV9Tn8s5wx61kSqVXKkHI5pMCKV8jAGarMOnHNTsvyBs8mo2T5uT1FSJjVQY+bBzTCBnIOcVLt6g9KY2DkAHPtQBXPQ5/Oo2zjkfSrTqCBnFVXyByc46UgIX4qu/C+9TuR1xmo3G7mgogfgcVXcjr0qeVcg+1VyDuoA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral condylar fracture with fragment displacement and rotation in a 2-year-old girl (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bachman D, Santora S. Orthopedic trauma. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_29_24031=[""].join("\n");
var outline_f23_29_24031=null;
